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Abstract 
Aspirin-intolerant asthma (AIA) is a syndrome where the interplay between cyclooxygenase (COX) 
and lipoxygenase (LOX) pathways is evident and is characterized by several abnormalities in the 
regulation and biosynthesis of eicosanoid mediators and eicosanoid receptors. Several observations 
indicate the presence of a complex change in the arachidonic acid (AA) metabolism in patients who 
suffer from AIA. However, previous studies showed some discrepant results when upper and lower 
airways were analyzed, and there are no clear explanations for this. The inflammatory responses in 
upper airways are often associated with the presence of nasal polyps, structures never seen in the 
lower airways. In this study, upper and lower airways were compared, in order to verify if the multiple 
factors of the COX pathway are differentially regulated considering both respiratory tracts. To perform 
the experiments, fibroblasts from nasal mucosa (NM) and bronchial mucosa (BM) of non-asthmatic 
subjects undergoing corrective surgery and fibrobronchoscopy, respectively, (control group) were 
compared with NM, nasal polyp (NP), and BM fibroblasts isolated from non-asthmatic and AIA patients 
suffering from chronic rhinosinusitis (CRS) with NP. The data presented in this investigation suggest 
that in lower airways, the presence of aspirin intolerance does not seem to alter the expression of 
COX enzymes or the production of prostaglandin (PG) E2. Considering the expression of the EP 
receptors, the data suggest significant differences through fibroblasts from upper airways tissues. The 
differences observed between upper and lower airways combined with others verified in previous 
studies might contribute to the pathogenesis of nasal polyposis.  
 
 
 
 
 
 
 
 
 
 
 
Keywords: Aspirin intolerant-asthma, cyclooxygenase, EP receptors, fibroblast, nasal polyp, 
prostaglandin E2, upper and lower airways. 
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Resumo 
A asma com intolerância à aspirina (AIA) é uma síndrome na qual existe uma estreita relação entre as 
vias da cicloxigenase (COX) e lipoxigenase (LOX) e é caracterizada por várias anomalias na 
regulação e biossíntese dos mediadores de eicosanóides e receptores de eicosanóides. Diversas 
observações indicam a presença de uma complexa alteração no metabolismo do ácido araquidónico 
(AA) em pacientes com AIA. Contudo, estudos anteriores reportaram alguns resultados discrepantes 
no que diz respeito às vias aéreas inferiores e superiores e não existe uma explicação clara para tal 
facto. A resposta inflamatória que ocorre nas vias aéreas superiores está frequentemente associada à 
presença de pólipos nasais, estruturas nunca observadas nas vias aéreas inferiores. Neste estudo, 
foram comparadas as vias aéreas superiores e inferiores, de modo a verificar se os múltiplos factores 
envolvidos na via da COX apresentam uma regulação diferencial em ambos os tratos respiratórios. 
Para a realização deste estudo foram isolados fibroblastos da mucosa nasal (NM) e mucosa 
brônquica (BM) de indivíduos não asmáticos submetidos a cirurgia correctiva do nariz e 
fibrobroncoscopia, respectivamente, (grupo controle), sendo posteriormente comparados com 
fibroblastos de NM, pólipo nasal (NP) e BM isolados de indivíduos não asmáticos e doentes com 
rinossinusite crónica (CRS) e NP. Os dados apresentados sugerem que, nas vias aéreas inferiores, a 
intolerância à aspirina não parece alterar a expressão das enzimas COX ou a produção de 
prostaglandina (PG) E2. Considerando a expressão dos receptores de prostaglandina E2 (EP), os 
resultados mostram diferenças significativas considerando fibroblastos isolados de tecidos 
provenientes das vias aéreas superiores. As diferenças observadas entre via superior e inferior, e 
tendo em conta outras diferenças verificadas em estudos anteriores, podem estar envolvidas no 
processo de formação de pólipos.  
 
 
 
 
 
 
 
 
 
 
Termos-chave: Asma com intolerância à aspirina, cicloxigenase, fibroblastos, pólipo nasal, 
prostaglandina E2, receptores EP, vias aéreas superiores e inferiores. 
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Upper airways
Lower airways
1. Introduction 
1.1. The Airways 
The main purpose of the respiratory system is to supply the body with oxygen and remove carbon 
dioxide, i.e., to promote gas exchange between our body and the external environment. The airway is 
a continuous and large structure that extends from de nasal vestibule to the alveoli. There is an 
imaginary line that divides the airways into two subdivisions: upper and lower airways (Figure 1.1) 
(Scadding and Kariyawasam, 2009). The upper airways, also known as the upper respiratory system, 
include the nose, the nasal cavity, the paranasal sinuses, the nasopharynx and the oropharynx. On 
the other hand, the lower respiratory system (lower airways) consists of the larynx, trachea, bronchi, 
and lungs (Jablonka and Rosenblatt, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation of the respiratory system. The figure represents the two sub-divisions of the 
airways (adapted from http://drraghu74.blogspot.com/2009/09/respiratory-system.html). 
 
The nose is an organ included in the upper airways that participates in several functions related to 
respiration. The major functions of the nose are to prepare the inhaled air, by filtering, warming, and 
moistening it before reaching the lungs. Since the nose acts as a filter and air-conditioner, it protects 
the lower airways. Effectively, the nose and their associated structures are the first site of allergen, 
microbial, and particle deposition (Scadding and Kariyawasam, 2009). Considering that, pathological 
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conditions of the nasal mucosa (NM) interfere with the nose functions, which can lead to increased 
exposure of the lower airways to allergens and subsequent airway inflammation (Braunstahl, 2011). 
 
 
1.2. Inflammation and Airway Inflammation 
Inflammation is a protective response initiated after injury through physical damage or infection by 
microorganisms. This essential biological process consists in eliminating the aberrant factors, promote 
tissue repair/wound healing, and establish memory. Inflammation is composed by an acute phase, 
which involves a large number of molecular, cellular and physiological changes. The acute phase is 
characterized by the rapid influx of blood granulocytes (neutrophils, monocytes, and macrophages). 
This mechanism is responsible to the cardinal signs of acute inflammation, as redness, heat, swelling, 
and pain. Concluded the set of responses, inflammation is resolved and the restoration of the inflamed 
tissue, as well as homeostasis is reestablished. However, if defects in the process occur, inflammation 
will persist and become chronic, lasting for longer periods, leading to excess tissue damage (Ricciotti 
and FitzGerald, 2011). 
Effectively, pro-inflammatory mediators generated in inflamed tissue drive to acute inflammation. 
However there is a systemic and local production of endogenous mediators that counter-balance the 
pro-inflammatory events occurred in these locals. Endogenous mediators are produced to avoid the 
development of chronic pathologies. For instance, lipid mediators derived from polyunsaturated fatty 
acids, such arachidonic acid (AA), are synthesized during the normal cell function, or after cell 
activation in stress conditions, in order to perform anti-inflammatory actions (Stables and Gilroy, 
2011). 
Diseases characterized by airway inflammation, excessive airway secretion, and airway obstruction 
affect a great proportion of the worldwide population. The excessive airway production of chemokines, 
cytokines, and growth factors in response to irritants, infectious agents, and inflammatory mediators 
may play an important role in the modulation of acute and chronic airway inflammation. Lipid 
mediators are chemical messengers that are released in response to tissue injury. These mediators 
may be produced by resident airway cells and by inflammatory cells or can be also altered by 
inflammatory cytokines (Levine, 1995).  
The main four signs of airway inflammation are edema (sweeling), vasodilatation (redness), cellular 
infiltration, and pain (increased airway responsiveness). Since the airways have no pain fibers, pain is 
defined, in this case, as an increase in airway responsiveness (Levine, 1995). 
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1.2.1. Airway Inflammatory Diseases 
1.2.1.1. Asthma 
Asthma is defined by the Global Initiative for Asthma as: “a chronic inflammatory disorder of the 
airways in which many cells and cellular elements play a role. The chronic inflammation is associated 
with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing, particularly at night or in the early morning. These episodes are usually 
associated with widespread, but variable, airflow obstruction within the lung that is often reversible 
either spontaneously or with treatment” (Muñoz-López, 2010).  
Asthma is a complex multifactorial disease of the airways and is currently a worldwide problem, with 
an estimation of 300 million of affected (Gohil et al., 2010). The disease may develop early in 
childhood or later on in life, and its pathogenesis seems to be associated with the interaction of 
several single-nucleotide polymorphism loci. The main features of asthma are airflow obstruction, 
chest tightness, wheezing and cough. The airflow obstruction is due mostly to smooth muscle 
contraction, bronchial wall edema and mucus plugging that leads to a partial or complete closure of 
the airways (Figure 1.2). There are many factors that can precipitate asthma attacks. These factors 
include allergy, viral infections, exercise, and airborne irritants, such as smoke cigarette or dusts. 
Asthma can be intermittent, or persistently mild, moderate or severe. The severity of the pathology 
varies among subjects and can change in one individual over time (O'Byrne, 2008). 
 
 
 
 
 
 
 
 
Figure 1.2. Normal versus asthmatic bronchiole (adapted from http://health.allrefer.com/health/asthma-normal-
versus-asthmatic-bronchiole.html).  
 
Pathophsysiologically, asthma is characterized by epithelial disruption, airway smooth muscle 
hypertrophy and hyperplasia, increased mucus secretion, basement membrane thickening, increased 
cytokine production and chronic infiltration of inflammatory cells. These changes that occur to a 
Normal Bronchiole Asthmatic Bronchiole 
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structural level are often referred as remodeling, that define complex morphological changes involving 
all structures within the bronchial wall (Hamid and Tulic, 2007; Blake, 2006; Fireman, 2003). 
Respiratory inflammation commonly affects both upper and lower respiratory tracts concurrently. 
Attention to the presence of asthma associated with other airway diseases, as rhinosinusitis is of 
importance while this condition often affects the quality of life more negatively as asthma alone 
(Marseglia et al., 2010). 
 
 
1.2.1.2. Chronic Rhinosinusitis and Nasal Polyposis  
Sinusitis involves inflammation of the sinus linings and rarely occurs without simultaneous rhinitis. 
Therefore, the usually term is a combination of both – rhinosinusitis. Rhinosinusitis is defined as an 
inflammatory process involving the mucosa and one or more sinuses (Scadding et al., 2008). The 
International Classification of Diseases divides rhinosinusitis into two forms: acute and chronic, 
according to the duration of symptoms. According with this classification, the acute form lasts up to 12 
weeks with complete resolution of symptoms. On the other hand, the chronic form that persists 
beyond 12 weeks is associated with significant morbidity and a lower quality of life (Fokkens et al., 
2005; Meltzer et al., 2004). Chronic rhinosinusitis (CRS) constitutes one of the most common health 
care problems and had direct medical costs as well as severe impact on lower airway diseases and 
general health outcomes (Fokkens et al., 2005). 
CRS is, as asthma, a multifactorial disease and is subdivided into two classes: CRS without nasal 
polyposis and CRS with nasal polyposis (Ferguson, 2004). Histologically, sinusal polyps are 
characterized by proliferation and thickening of mucosal epithelium with focal squamous metaplasia, 
glandular hyperplasia, subepithelial fibrosis, and stromal edema with numerous blood vessels. The 
most common inflammatory cells that appear in nasal polyps (NPs) are the eosinophils, but 
fibroblasts, mast cells and goblet cells are also present (Fokkens et al., 2005). NP and CRS are 
considered many times as only one disease, because the differentiation between them is very 
complicate and nearly impossible. CRS associated with nasal polyposis is very difficult to treat, while 
its etiology and pathophysiology are still unclear, and even after surgery and medical treatments, 
recurrences are frequent. Patients with NPs often present other related diseases, such as asthma, 
aspirin intolerance, sinobronchial syndrome, or cystic fibrosis (Pawankar and Nonaka, 2007).  
Clinically, the diagnostic of CRS requires two or more of the following symptoms: nasal blockage, 
anterior or postnasal drip, facial pain or pressure, and reduced or absent sense of smell. Besides, 
there is an endoscopic intervention that allows document the presence or absence of inflammation 
(Pawankar and Nonaka, 2007). 
 
 
 
Introduction 
5 
 
1.2.1.3. Aspirin-Intolerant Asthma 
Aspirin-intolerant asthma (AIA) is a distinct clinical syndrome characterized by the association of 
asthma, CRS, bilateral nasal polyposis, and episodes of bronchospasm precipitated by non-steroidal 
anti-inflammatory drugs (NSAIDs) (Stevenson and Szczeklik, 2006). The first case of AIA was 
reported in 1922 by Widal and collaborators, when an episode of bronchospasm was observed 
following the ingestion of acetyl salicylic acid (aspirin) in a subject who suffer from asthma (Varghese 
and Lockey, 2008). In the late 1960’s, Samter and Beers described this peculiar syndrome with its 
clinical triad of asthma, nasal polyposis, and aspirin intolerance, in greater detail (Samter and Beers, 
1968).  
Actually, aspirin and NSAIDs are among the most widely used medication in the world. Aspirin and 
other NSAIDs are prescribed to treat and prevent heart diseases, as well as used to antipyretic, anti-
inflammatory, and analgesic therapy. Normally, for most of people, these drugs are well tolerated, but 
asthmatic patients are an exception. In several patients with bronchial asthma, aspirin and other 
NSAIDs are capable to precipitate attacks of asthma. The severity of the attacks is variable, 
depending on the patient (Szczeklik and Sanak, 2006). Considering that, AIA is actually recognized to 
be an aggressive phenotype of airway disease that often runs a protracted course. When compared 
with aspirin-tolerant (AT) subjects, patients with AIA are more susceptible to experience irreversible 
airway flow obstruction, to suffer frequent exacerbations, as well as to be diagnosed with severe 
asthma (Koga et al., 2006; Mascia et al., 2005). 
The exposure to aspirin or other NSAIDs does not initiate or perpetuate the underlying respiratory 
inflammatory disease. However, since the disease is ongoing, these drugs induce release or synthesis 
of critical mediators (Gohil et al., 2010). After ingestion of aspirin or NSAIDs, patients with adverse 
reactions develop symptoms within 2 – 3 hours. Symptoms generally consist of bronchospasm, 
profuse rhinorrhea, conjunctival injection, periorbital edema, and generalized flushing (Morwood et al., 
2005; Szczeklik and Stevenson, 2003).  
This peculiar syndrome is presents in approximately 3 to 20% of the adult asthmatic population, and is 
more frequent in women than in men (Gohil et al., 2010). Additionally, in women the symptoms 
emerge normally earlier, and the disease seems to be more aggressive (Szczeklik et al., 2000). 
Aspirin sensitivity has been reported in 35 – 52% of patients with NPs and in as many as 65% of 
patients who suffer from both bronchial asthma and nasal polyposis (Schiavino et al., 2000). Patients 
with aspirin/NSAID-induced respiratory reactions often have an underlying history of asthma, nasal 
polyposis, and/or rhinosinusitis (Gollapudi et al., 2004), although some patients may not have any 
predisposing diseases. Subjects who develop the aspirin triad typically develop persistent rhinitis in 
their third or fourth decade of life and, approximately 2– 5 years later, there is a progression to 
asthma, aspirin sensitivity, and nasal polyposis (Hamad et al., 2004).  
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Aspirin sensitivity is not considered an immunological reaction, because the pathology did not involve 
an immunoglobulin (Ig) E-mediated reaction (Pfaar and Klimek, 2006). The pathological mechanism 
responsible for the development of AIA has not been completely elucidated. However, several 
observations suggest that abnormalities in the regulation of AA may be involved in the adverse 
response to NSAIDs in patients with this pathology (Yoshimura et al., 2008; Stevenson and Szczeklik, 
2006). 
 
 
1.3. AA Metabolic Pathways 
AA, a 20-carbon polyunsaturated fatty acid (20:4 ω-6), is the main eicosanoid precursor. Under normal 
conditions the concentration of free AA within the cells is low. Most of it is stored as part of 
phospholipids in the membranes of the cells (Brash, 2001). The availability of free AA is essential for 
the biosynthesis of eicosanoids. Therefore, this mediator is released from the phospholipid 
membranes by the action of various phospholipase enzymes, which are activated in response to 
different stimulus (physical, chemical, hormonal, cytokines, etc) (Figure 1.3). The mainly enzyme 
implicated in the release of AA seems to be the cytosolic phospholipase A2 (Picado, 2006). When AA 
is released from the membrane, it is rapidly metabolized in several enzymatic and non-enzymatic 
pathways to yield an important family of oxygenated products, collectively termed eicosanoids, 
released from the source cell and act in an autocrine/paracrine manner on target cells. The three main 
enzymatic pathways responsible to the metabolism of AA include (1) the lipoxygenase (LOX) pathway, 
responsible to the formation of leukotrienes (LTs) and lipoxins, (2) the cyclooxygenase (COX) 
pathway, involved in the formation of prostaglandins (PGs), thromboxanes (Txs), and prostacyclin, 
and (3) the cytochrome P450, responsible for the formation of epoxyeicosatrienoic and 
hydroxyeicosatetraenoic acids (Stables and Gilroy, 2011; Simmons et al., 2004).   
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic representation of AA release process. Membrane-bound phospholipids are converted to 
AA by the action of phospholipase enzymes, which are activated in response to external stimuli (adapted from 
Stratton and Alberts, 2002). 
Arachidonic Acid 
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1.3.1. COX Pathway 
COX is a bi-functional enzyme involved in the COX pathway. COX-1 and COX-2 isoenzymes catalyze 
the same reactions, show approximately 60 – 65% identity in their amino acid sequence within a given 
species, but are encoded by two different and specific genes, located in distinct chromosomes. These 
enzymes are located in the lumenal portion of the endoplasmic reticulum membrane and the nuclear 
envelope (Chandrasekharan and Simmons, 2004). COX-1 serves a number of physiologic 
“housekeeping” functions, such as modulation of platelet aggregation and cytoprotection in the 
gastrointestinal mucosa. In addition, the expression of COX-1 is developmentally regulated in many 
different tissues, and small changes in expression can occur after stimulation with hormones or growth 
factors (Rocca and FitzGerald, 2002). On the other hand, COX-2 is highly induced in macrophages, 
fibroblasts, vascular endothelial cells, and smooth muscle cells by various cytokines, endotoxins, 
growth factors, or tumor promoters. COX-2 is the more important source of prostanoid formation in 
inflammatory processes (Baigent and Patrono, 2003). A third form (COX-3) has also been described, 
although recent studies indicate that this form represents a splice variant of COX-1 that encodes a 
truncated protein lacking enzymatic activity (Snipes et al., 2005). 
AA can be metabolized by COX enzymes (Figure 1.4). Once AA is released, COX isoenzymes 
catalyze the cyclization of AA to form PGH2 through a two-step redox reaction: (1) AA is oxidized by 
the COX enzymes into the unstable intermediate PGG2 in the active site of the enzyme and then (2) 
PGG2 is reduced by the peroxidase activity of COX to form PGH2. PGH2 is the precursor of several 
bioactive prostanoids, which are formed by the action of specialized tissue isomerases. The five 
prostanoids synthesized by this pathway include PGE2, as well as PGD2, PGF2α, PGI2, and TxA2 
(Rocca, 2006). After the synthesis, the prostanoids exit the cells in order to activate G-protein-coupled 
receptors or nuclear receptors in target cells. The prostanoid receptor subfamily is comprised of eight 
members (DP, EP1-4, FP, IP, and TP), which are classified according to the prostanoid ligand that 
each binds with greatest affinity (Hata and Breyer, 2004).  
PGE2, PGD2, PGF2α, PGI2, and TxA2 are metabolites that exert their biological effects in the proximity 
of the sites of their synthesis, in autocrine or paracrine manner. These mediators play an important 
role in the inflammatory process. In inflamed tissues, their biosynthesis is significantly increased, and 
they contribute to the development of the main signs of acute inflammation. Moreover, during an 
inflammatory response, the level and profile of PG production change significantly (Ricciotti and 
FitzGerald, 2011). 
PGE2 is one of the most abundant prostanoid produced in the body and exhibits versatile biological 
activities. Additionally, it seems to have an important role in inflammatory processes (Ricciotti and 
FitzGerald, 2011). As previously described, the activity of PGE2 is mediated by four receptors, termed 
prostaglandin E2 receptors (EP) (EP1 – EP4), which are encoded by distinct genes and have divergent 
amino acid sequences, but all bind PGE2 with high affinity. Thus, through the multiple receptor 
subtypes, PGE2 can trigger several intracellular signal transduction pathways and has diverse final 
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effects, which sometimes seem to be functionally opposing within the same cell or organ (Rocca, 
2006). The complexity of PGE2 responses is further complicated by evidence that multiple EP 
receptors are often co-expressed or induced in the same cell or organ. The regulation of this co-
expression is still unknown, but it indicates that the response to PGE2 is modulated, based on the 
activation of different pathways by different EP receptor subtypes (Rocca, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Representation of the COX pathway, showing the several prostanoids and the receptors through them 
act. AA is converted to PGH2 through a two-step process that involves COX activity to convert AA to PGG2 
followed by a peroxidase reaction, mediated also by COX enzymes to produce PGH2. The formation of the 
several PGs is carried out by tissue-specific isomerases (adapted from Ricciotti and FitzGerald, 2011). 
 
EP1 activates phosphotidylinositol metabolism leading to the formation of inositol triphosphate with 
mobilization of intracellular free calcium. EP2 and EP4 stimulate adenylate cyclase, leading to the 
production of cyclic adenosine 3’, 5’-monophosphate (cAMP), which activates the cAMP-dependent 
protein kinase A. Stimulation of EP4 also activates phosphoinositide-3’-kinase. EP3 is the only 
receptor that possesses multiple splice variants and the different isoforms couple to multiple G 
proteins producing either inhibition of adenylate cyclase or stimulation of adenylate cyclase activity 
(Figure 1.5) (Vancheri et al., 2004). 
TP DP EP1, EP2, EP3, EP4 IP FP
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↑ Ca2+ ↑ cAMP ↑ / ↓Ca2+
↑ / ↓cAMP
 
Figure 1.5. Schematic representation of EP receptors signaling (adapted from www.yorku.ca/dakc/research.html). 
 
PGE2 can exert both pro-inflammatory and anti-inflammatory effects, and these actions are often 
produced through regulation of receptor gene expression in relevant tissues. For instance, 
hyperalgesia, a sign of inflammation, is mediated mainly by PGE2 through EP1 receptor (Moriyama et 
al., 2005). Other studies have also implicated EP3 receptor in the inflammatory pain response 
mediated by low doses of PGE2 (Minami et al., 2001). On the other hand and in some cases, PGE2 
acting through the EP2 receptor has been shown to inhibit leukocyte cytokine production, chemotaxis, 
and superoxide generation as well as mast cell histamine release, revealing anti-inflammatory 
proprieties of this receptor (Ying et al., 2006). A recent study had demonstrated that EP4 receptor is 
responsible for PGE2-induced relaxation of human airway smooth muscle, showing bronchodilator 
effects of this receptor (Buckley et al., 2011). 
As opposed to many other parts of the body, the lungs represent a peculiar site for the action of PGE2. 
At this level, the concentration of PGE2 is normally much higher than in plasma, and evidence suggest 
that, in this specific tissue, PGE2 has a different role and its increase might be of therapeutic benefit 
(Vancheri et al., 2004). Effectively, in the lungs PGE2 has a role in limiting the immune inflammatory 
response as well as in controlling tissue repair processes. For instance, in bronchial asthma, PGE2 
prevents early and late allergen-induced bronchoconstriction, and reduces airways 
hyperresponsiveness and inflammation. Additionally, evidence suggest that the inhalation of PGE2 can 
prevent the symptoms provoked by allergens. PGE2 controls other important aspects of allergic 
inflammation by reducing eosinophil degranulation and inhibiting TxA2 and cysteinil LTs (Cys-LTs) 
synthesis; both of them are considered potent bronchoconstrictors of asthmatic airways. Additionally, 
PGE2 reduces AA-induced release of TxA2 from human bronchial biopsies, and regulates the 
synthesis of LT biosynthesis (Vancheri et al., 2004). 
Several studies have been performed in order to demonstrate the regulatory role of PGs in 
inflammation, more specifically on the feedback control of COX enzymes. These investigations 
suggest the presence of a positive feedback of PGE2 on COX-2 expression, but not in COX-1 protein 
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expression (Vichai et al., 2005). Effectively, a deeper knowledge about the relationship between the 
PGs and the COX enzymes might be useful to develop new therapeutic approaches.  
 
 
1.3.2. LOX Pathway 
AA is also metabolized by LOX enzymes, found as 5-, 12-, and 15-LOX. 5-LOX plays an important 
role in the inflammation because it is responsible to the LT synthesis. Thus, this section will be based 
on this specific pathway (Picado, 2006). 
The 5-LOX is responsible for the production of substances of anaphylaxis, as LTC4, LTD4, and LTE4, 
which are potent mediators of allergic response, and LTB4, which is a powerful polymorphonuclear 
leukocyte chemoattractant. Upon activation, 5-LOX interacts with its processing protein, FLAP, 
allowing the oxygenation of AA. The product of 5-lipoxygenation of AA, LTA4, can be transformed, in 
some cells, into LTB4 or into LTC4. The LTC4 is then transported to the exterior of the cells, where is 
metabolized into LTD4, which can be further modified into LTE4 (Figure 1.6). 5-LOX, contrary to COX 
enzymes, is inactive in quiescent cells but becomes enzymatically functional when the cells are 
activated by the increase of intracellular calcium (Stables and Gilroy, 2011).  
LTC4, LTD4, and LTE4 form the Cys-LTs. The Cys-LTs act through specific receptors (Cys-LTs 
receptor 1 and 2) of the rhodopsin class, located on the outer leaflet of the plasma membrane. Once 
bound to a specific receptor, is sent a signal via G-protein in the cytoplasm to increase intracellular 
calcium and block formation of cAMP, which alters several cellular activities. The Cys-LTs are 
responsible to the development of bronchoconstrictor effects, mucus secretion, and edema 
accumulation in airways (Gohil et al., 2010; Picado, 2006). In patients with asthma or CRS who suffer 
from aspirin intolerance it was observed an over-expression of Cys-LTs receptor 1 (Sousa et al., 
2002). 
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Figure 1.6. Representation of the LT metabolism. AA is converted into LTA4 by the action of 5-LOX and FLAP. 
LTA4 can be transformed into LTB4 or LTC4. LTC4 is metabolized into LTD4, which is further transformed into LTE4 
(adapted from Stables and Gilroy, 2011). 
 
 
1.4. Alterations in AA Pathway 
AIA is a clinical syndrome where the interplay between the two enzymatic pathways (COX and LOX) is 
evident and is characterized by several abnormalities in the biosynthesis of eicosanoid mediators and 
eicosanoid receptors. Effectively, there are several observations that indicate the presence of a 
complex change in the AA metabolism of NSAID-intolerant asthmatic patients. Additionally, these 
alterations affect practically all the pathways (Picado, 2006; Vancheri et al., 2004).   
The LOX pathway is more activated in asthmatic patients in basal conditions when compared with 
control subjects. Moreover, this pathway seems to be more activated in patients with AIA than in 
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tolerant patients (Picado, 2006). It has been suggested that in patients who suffer from AIA, COX 
inhibition by aspirin or other NSAIDs might cause shunting of AA into the 5-LOX pathway. This specific 
condition triggers the synthesis of the bronchoconstrictor and vasoactive Cys-LTs (LTC4, LTD4, and 
LTE4) by the 5-LOX/LTC4 synthase pathway (Figure 1.7) (Adamjee et al., 2006; Vancheri et al, 2004). 
Several studies have demonstrated that in both upper and lower airways of patients who suffer from 
AIA, the 5-LOX pathway of AA is significantly up-regulated. Additionally, it was verified that the critical 
enzyme responsible for Cys-LT production (LTC4 synthase) is much higher in the airways of patients 
with AIA compared with AT asthmatic patients and control subjects (Gohil et al., 2010; Adamjee et al., 
2006; Cowburn et al., 1998). Thus, the abnormal activity of the 5-LOX pathway leads to the baseline 
over-production of Cys-LTs in patients with AIA, which is further increased when patients are exposed 
to aspirin or other NSAIDs (Kowalski et al., 2000; Picado et al., 1992). 
Several abnormalities have also been described in COX pathway of patients with AIA (Stevenson and 
Szczeklik, 2006; Picado, 2006). However, the role of COX enzymes in the pathogenesis of AIA is less 
clear, when compared with the role of LTs. Clinical studies show that inhibition of COX-1, but not 
COX-2, precipitates asthmatic attacks (Szczeklik and Sanak, 2006). COX-1 inhibitors accelerate 
depletion of PGE2, which would normally protect against the bronchoconstriction and mast-cell 
mediator release effects (Szczeklik and Stevenson, 2003). Additionally, expression of the COX-2 
enzyme and its activity are reduced in patients with AIA (Szczeklik and Sanak, 2006). The 
combination of a low activity of COX-2 in aspirin-sensitive subjects with the inhibition of COX-1 by 
aspirin and other NSAIDs may contribute to reduced PGE2 production. Effectively, numerous studies 
that assessed PGE2 production in patients who suffer from AIA have reported a reduced production of 
PGE2 associated with a down-regulation in the expression of both COX-1 and COX-2 in NP tissues, as 
well as in fibroblasts and epithelial cells derived from NPs of patients with aspirin-intolerance (Roca-
Ferrer et al., 2011; Yoshimura et al., 2008; Pérez-Novo et al., 2005; Pujols et al., 2004; Picado et al., 
1999). On the other hand, and contrary to the results obtained in NPs, studies that used cultured 
fibroblasts and bronchial biopsies have not find any differences in the expression of both COX-1 and 
COX-2 enzymes between patients with AIA and AT or in control subjects (Pierzchalska et al., 2003; 
Cowburn et al., 1998). 
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Figure 1.7. Schematic representation of the aspirin/NSAIDs effects in patients with AIA. The image shows the 
shunting of AA into the 5-LOX pathway, when COX pathway is inhibited by aspirin or other NSAIDs in patients 
with AIA.  
 
The expression of EP receptors also seems to be altered in patients who suffer from AIA. A study 
performed to measure the expression of all EP receptors in nasal biopsies from patients with and 
without aspirin sensitivity demonstrated a reduced number of eosinophils that express EP2 receptor in 
NP samples from patients with AIA, when compared with AT patients (Ying et al., 2006). Moreover, it 
was reported that a pro-inflammatory stimulus, as interleukin (IL)-1β, stimulates the expression of EP2 
in cultured fibroblasts from NM of control subjects, but has no effect on EP2 expression in cultured 
fibroblasts from NP-AIA. Since PGE2 acts, in some cases, through EP2 receptor to mediate anti-
inflammatory responses, the alterations verified to the EP2 receptor, as reduced expression, might be 
involved in the increase of the inflammatory process in the airways of patients who suffer from AIA, 
when compared with control subjects (Roca-Ferrer et al., 2011). 
 
 
1.5. Experimental Model 
In vitro cell-based studies have allowed detailed investigations of the molecular mechanisms 
underlying the pathology of airway diseases. The fibroblasts are cells that can be used as model to 
investigate the mechanisms involved in the process of inflammatory airway diseases. In our 
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laboratory, for instance, fibroblasts are isolated from human tissue explants, obtained during surgical 
procedures. These samples preserve many of the in vivo tissue characteristics of each patient that 
participate in the study, for instance the cells retain the AA abnormalities reported in the patients who 
suffer from AIA. Effectively, previous studies that assessed the production of PGE2, the expression of 
COX enzymes, and the expression of all EP receptors have used cultured fibroblasts as in vitro model 
(Roca-Ferrer et al., 2011).  
 
 
1.6. Hypothesis 
As previously described, several anomalies in the COX pathway in AIA have been reported, but some 
discrepancies were found when comparing upper and lower airways. These discrepancies might be 
due, at least in part, because de regulation of AA metabolism was extensively studied in upper 
airways but not in lower airways.  
Upper and lower airways histology and physiology show many similarities and some differences, for 
instance smooth muscle is present in lower airways and not in upper airways. In addition, some 
inflammatory diseases that affect the upper airways (rhinitis and sinusitis) share some common 
physiopathological mechanisms with those affecting the lower airways (asthma). However, the 
inflammatory response in upper airways is sometimes associated with the presence of polyps, 
inflammatory structures never seen in the lower airways of patients who suffer from asthma and other 
inflammatory diseases of the lower airways. Effectively, most of the alterations of the COX pathway 
were verified in patients with nasal polyposis, and these alterations might be involved in the 
pathogenesis of nasal polyposis. Considering that, it was hypothesized that the abnormalities reported 
in the COX pathway are specific of NPs and not representative of the lower airways mucosa.  
Additionally, there were found differences in the expression of EP receptors in nasal tissues. However, 
there are no studies that evaluate the expression of EP receptors in both upper and lower airways. 
Considering that, it was also hypothesized that differences in the expression of EP receptors also exist 
between upper and lower airways.  
 
 
1.7. Objectives 
1.7.1. General Objectives 
To compare the secretion of PGE2 and the expression of both COX enzymes (COX-1 and COX-2) and 
all EP receptors (EP1 – EP4) in upper and lower airways of control subjects, patients aspirin-tolerant 
who suffer from CRS with NPs, and patients aspirin-intolerant who suffer from bronchial asthma and 
CRS with NPs.  
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1.7.2. Specific Objectives 
1. To investigate the secretion of PGE2 at baseline and after cell stimulation with a pro-inflammatory 
stimulus for 24 hours. 
2. To analyze the expression of COX-1 at baseline and after cell stimulation with a pro-inflammatory 
stimulus for 24, 48, and 72 hours.  
3. To study the expression of COX.2 at baseline and after cell stimulation with a pro-inflammatory 
stimulus for 24 hours. 
4. To study the expression of COX-1 and COX-2 after cell stimulation with PGE2 at different 
concentrations for 24 hours.  
5. To analyze the expression of each EP (EP1 - EP4) receptor at baseline and after cell activation with 
a pro-inflammatory stimulus for 24, 48, and 72 hours.  
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2. Materials and Methods 
In Table 2.1 is represented the list of all material and reagents used to carry out the experimental 
protocols, as well as their origin.  
 
Table 2.1. List of materials and reagents. 
Materials and Reagents Origin 
6-well culture plates NUNC, Wiesbaden, Germany 
24-well culture plates NUNC, Wiesbaden, Germany 
96-well culture plates NUNC, Wiesbaden, Germany 
75-cm
2 
culture flasks NUNC, Wiesbaden, Germany 
150-cm
2 
culture flasks NUNC, Wiesbaden, Germany 
0.05% Trypsin – 0.02% Ethylenediaminetetraacetic 
acid 
Invitrogen, United Kingdom 
4',6-diamidino-2-phenylindole Sigma Chemical Co., St. Louis, USA 
Agarose Conda Laboratories, Spain 
Amphotericin B solution (2μg/mL) Sigma, St. Louis, USA 
Bovine Serum Albumin Sigma Chemical Co., St. Louis, USA 
Cell Proliferation Kit II (XTT) 
 XTT labelling reagent 
 Electron-coupling reagent 
Roche Diagnostics, Mannheim, Germany 
Complete
TM
 Mini Protease Inhibitor Cocktail Tablets Roche Diagnostics, Mannheim, Germany 
Cryoprotective media Lonza, Walkersville, USA 
CultureSlides® NUNC, Rochester, USA 
Dimethyl Sulfoxide Sigma, St. Louis, USA 
Dulbecco’s modified Eagles’s media  Lonza, Walkersville, USA 
Eagle’s minimal essential media  Lonza, Walkersville, USA 
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Extracellular cell matrix gel E1270, Sigma Chemical, St. Louis, USA 
Fetal Bovine Serum Gold (Lot A15108-1952) PAA Laboratories GmbH, Cölbe, Germany 
Hepes Buffer Solution at 0.05M Gibco-Invitrogen, Stockholm, Sweden 
Neubauer chamber Blaubrand, Wertheim, Germany 
Paraformaldehyde at 4% Proquinorte, Spain 
Pefabloc SC Roche Diagnostics, Mannheim, Germany 
Penicillin (100IU/mL) – Streptomycin (100µg/mL) Invitrogen, Carlsbad, USA 
Phosphate Buffered Saline 10X without Ca and Mg Lonza, Belgium 
Phosphate Buffered Saline, pH = 7.4 Sigma, St. Louis, USA 
PCR Mycoplasma Detection Kit Minerva Biolabs, Germany 
ProLong Gold antifade reagent Invitrogen, USA 
Protein Assay Kit 
 Protein Standard Solution 
 Lowry Reagent 
 Folin & Ciocalteau’s Phenol Reagent 
 Working Solution 
Sigma, St. Louis, USA 
Prostaglandin E2 EIA Kit – Monoclonal Cayman Chemical, Ann Arbor, Mich 
UltraPure™ 10X 
TRIS/Borate/Ethylenediaminetetraacetic Acid Buffer 
Invitrogen, Carlsbad, USA 
Restore
TM
 Western Blot Stripping Buffer Thermo Scientific, Rockford, USA 
Super Signal® West Pico Chemiluminescent 
Substrate 
Thermo Scientific, Rockford, USA 
SYBR® Safe DNA gel Stain Invitrogen, Oregon, USA 
Triton X-100 Sigma Chemical Co., St. Louis, USA 
Trypan Blue Solution at 0.4% Sigma , St. Louis, USA 
Tween®20 Sigma, St. Louis, USA 
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NuPAGE® lithium dodecyl sulfate sample buffer 4X Invitrogen, Carlsbad, USA 
NuPAGE® sample reducing agent 10X Invitrogen, Carlsbad, USA 
7% TRIS-acetate gels Invitrogen, Carlsbad, USA 
Novex TRIS-acetate sodium dodecyl sulfate 
Running Buffer 20X 
Invitrogen, Carlsbad, USA 
NuPAGE® Antioxidant Invitrogen, Carlsbad, USA 
SeeBlue® Plus2 Pre-Stained Standard Invitrogen, Carlsbad, USA 
iBlot® Anode Stack Invitrogen, Carlsbad, USA 
iBlot® Cathode Stack Invitrogen, Carlsbad, USA 
iBlot® Filter Paper Invitrogen, Carlsbad, USA 
iBlot® Disposable Sponge Invitrogen, Carlsbad, USA 
Prostaglandin E2, 14010 Cayman Chemical, Ann Arbor, USA 
Recombinant Human Interleukin-1β, 201-LB R&D Systems, Minneapolis, USA 
Human α-smooth muscle actin monoclonal 
antibody, M0851 
DAKO, Glostrup, Denmark 
Human vimentin monoclonal antibody, V5255 Sigma, St. Louis, USA 
Pan-cytokeratin monoclonal antibody, C2562 Sigma, St. Louis, USA 
Human Cyclooxygenase-1 polyclonal antibody, sc-
1752 
Santa Cruz Biotechnology, USA 
Human Cyclooxygenase-2 monoclonal antibody, 
160112 
Cayman Chemical, Ann Arbor, USA 
Human EP1 polyclonal antibody, 101740 Cayman Chemical, Ann Arbor, USA 
Human EP2 polyclonal antibody, 101750 Cayman Chemical, Ann Arbor, USA 
Human EP3 polyclonal antibody, 101769 Cayman Chemical, Ann Arbor, USA 
Human EP4 polyclonal antibody, ab45863 Abcam, Cambridge, UK 
β-actin monoclonal antibody, A2228 Sigma, St. Louis, USA 
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Goat anti-rabbit IgG-HRP, sc-2004 Santa Cruz Biotechnology, Santa Cruz, USA 
Goat anti-mouse IgG-HRP, sc-2005 Santa Cruz Biotechnology, Santa Cruz, USA 
Donkey anti-goat IgG-HRP, sc-2020 Santa Cruz Biotechnology, Santa Cruz, USA 
Alexa Fluor 488 goat anti-mouse IgG, A11029 Invitrogen, Carlsbad, USA 
 
 
2.1. Study Population 
NM specimens were obtained from 20 non-asthmatic subjects with septal deviation, turbinate 
hypertrophy or both undergoing nasal corrective surgery (control-NM). All the control subjects had 
taken aspirin or NSAIDs at clinical dosage without any adverse reaction as asthma and/or rhinitis, 
urticaria, angioedema, or anaphylaxis. NM specimens were also collected from 10 asthmatic patients 
with CRS and AIA (NM-AIA) undergoing functional endoscopy surgery. Additionally, by means of 
fibrobronchoscopy during the surgery, samples of BM were collected from some of the control 
subjects (n = 5) and AIA patients (n = 5). NP specimens were collected from 18 patients with AIA (NP-
AIA) and from 15 patients without asthma who tolerate aspirin (NP-AT) during the functional 
endoscopy surgery.  
The main demographic data and clinical characteristics of the study population are shown in Table 
2.2. The diagnosis of AIA was made on the basis of a clear-cut history of asthma attacks precipitated 
by NSAIDs and confirmed by lysine-aspirin nasal challenge as previously described (Casadevall et al., 
2000) in patients with an isolated episode of NSAIDs-induced asthma exacerbation. None of the 
control subjects had a history of nasal or sinus diseases (chronic rhinitis/rhinosinusitis) or had taken 
oral or intranasal corticosteroids for at least one month before surgery. None of the control subjects 
and patients has suffered from upper or lower airway infection during at least two weeks prior to 
surgery. All patients and control subjects gave an informed consent to participate in the study, which 
was approved by the Scientific and Ethics Committee of our Institution. 
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Table 2.2. Demographic data and clinical characteristics of the study population. 
Characteristics Control-NM NM-AIA NP-AT NP-AIA Control-BM BM-AIA 
Fibroblast 
cultures, n 
20 10 15 18 5 5 
Age, years 
(mean ± SEM) 
44.4 ± 4.5 42.3 ± 3.5 49.1 ± 3.9 49.2 ± 3.4 32.8 ± 3.8 39.6 ± 2.8 
Female, n (%) 2 (10) 5 (50) 2 (13.3) 11 (61.1) 1 (20) 3 (60) 
Asthma, n (%) 0 (0) 10 (100) 0 (0) 18 (100) 0 (0) 5 (100) 
AIA, n (%) 0 (0) 10 (100) 0 (0) 18 (100) 0 (0) 5 (100) 
Skin prick test 
positivity, n (%) 
1 (5) 2 (20) 4 (26.7) 6 (33.3) 0 (0) 2 (40) 
Intranasal 
corticosteroid, n 
(%) 
0 (0) 7 (70) 9 (60) 16 (88.9) 3 (60) 5 (100) 
AIA, aspirin-intolerant asthmatic; AT, aspirin-tolerant; BM, bronchial mucosa; NM, nasal mucosa; NP, nasal polyp 
 
 
2.2. Tissue Handling and Cell Culture 
NM and NP samples were cut into pieces of 3 X 3 mm approximately and placed in 6-well culture 
plates (Figure 2.1) containing 1mL of culture media (Dulbecco’s modified Eagle’s media (DMEM) 
supplemented with 10% of fetal bovine serum (FBS), 100IU/mL penicillin, 100μg/mL streptomycin, and 
2μg/mL amphotericin B). The same batch of FBS was used for the whole experimental period. Since 
the size of the BM is very small, the tissue sections were placed on 6-well culture plates with 50µL of 
an extracellular cell matrix (ECM) gel (contains laminin as a major component, collagen type IV, 
heparan sulphate proteoglycan, entactin and other minor components) to fix the samples to the plastic 
surface. ECM gel polymerized when brought to 20 – 40°C to form a basement membrane. Then, 1mL 
of culture media was added to each well. Tissue pieces were kept in a 5% CO2 incubator (NuAIRE US 
Autoflow) at 100% humidity and 37ºC. Culture media was changed every 2 to 3 days.  
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Figure 2.1. Representation of fibroblast cultures. A, NP samples were cut into small pieces and placed in a 6-well 
culture plate with culture media; B, Microscopic view of fibroblasts growing from the NP sample piece (original 
magnification 4X). 
 
Cells growth was assessed every day using an inverted optical microscope (Leica DM IRB, Leica 
Mycrosystems). When fibroblasts began to proliferate (approximately after a minimum of 3 weeks), the 
tissue fragments were removed and the first passage was performed. For passaging, cells were 
washed once with phosphate buffered saline (PBS) 1X and detached by treating with warm 0.05% 
trypsin / 0.02% ethylenediaminetetraacetic acid (EDTA) for five minutes at 37ºC. The reaction was 
stopped with culture media and cells were centrifuged at 400g for 5 minutes (Hermle Z400K 
centrifuge, Phenix Research, NC, USA).  
Cells were resuspended in culture media, seeded, and grown to 80% confluence in 75-cm
2 
culture 
flasks. Then, fibroblasts were trypsinized and cultured to subconfluence in CultureSlides® and 150-
cm
2
 culture flasks to perform culture characterization and experimental protocols, respectively.  
For long-term storage, subconfluent cells were trypsinized and centrifuged using the same protocol 
explained before. The cell suspension was resuspended in Eagle’s minimal essential media (EMEM) 
supplemented with 20% FBS and in a solution of cryoprotective media (Basal Eagle’s media with 
Hank’s and 15% dimethyl sulfoxide (DMSO) without L-glutamine). All the process was performed 
A 
B 
Materials and Methods 
23 
 
under sterile conditions. Cells were transferred to appropriate cryovials and frozen by slow cooling. 
After that, cells were stored under liquid nitrogen. When required, cells were thaw from liquid nitrogen 
and seeded with fresh culture media in order to perform new experimental protocols. 
 
 
2.3. Polymerase Chain Reaction Mycoplasma Detection Kit 
When a cell-line is kept in culture, is important to test the cells for mycoplasma contamination, since 
mycoplasma may induce cellular changes, including chromosome aberrations, changes in metabolism 
and cell growth. The presence of mycoplasma was analyzed using the polymerase chain reaction 
(PCR)-based mycoplasma detection kit VenorGeM. It is a very sensitive test since it requires 
approximately only 1 to 5fg of mycoplasma deoxyribonucleic acid (DNA). The primers contained in this 
kit are designed for a specific region of the 16S ribonucleic acid (RNA), which is highly conserved on 
many Mycoplasma strains. The sample is mycoplasma-positive when the result is a 270 base pairs 
(bp) fragment. The kit provides also an internal control DNA, which can be added to the reactions. 
When the PCR is carried out with the internal control DNA, a successfully performed reaction is 
indicated by a 192 bp fragment on the agarose gel.    
Samples and PCR protocol were prepared according to the instructions of the supplier. Briefly, in 
order to prepare the templates for this PCR assay, 100μL of the cell culture supernatant was collected 
in a sterile tube and boiled for 5 minutes, at 95ºC in a thermocycler (MJ Research PTC-100, USA). 
After that, the tube was briefly centrifuged for 5 seconds to pellet cellular debris.  
PCR reactions were carried out in a final volume of 50μL. Each reaction was performed by using a 
positive (DNA fragments of Mycoplasma orale genome, kit) and a negative (sterile de-ionized water) 
control, as well as an internal control. In Table 2.3 the instructions for Mastermix preparation are 
represented. The final volume of the Mastermix was 48μL. 
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Table 2.3. Mastermix for the PCR reaction. 
 Volume per reaction (μL) 
Sterile deionized water 34.6 
10X Reaction Buffer (blue cap) 5.0 
Primer/Nucleotide Mix (red cap) 5.0 
Internal Control 2.0 
TAQ Polymerase (5U/μL)  0.4 
MgCl2 1.0 
 
2μL from the prepared cell culture were added into the reaction tube except on the tube that contains 
both negative and positive controls. In these tubes, 2μL of DNA template supplied for positive control, 
and 2μL of water for negative control were added. The amplification was performed in a thermal cycler 
(MiniCycler PTC-150 Thermal Cycler, MJ Research, USA) using the thermal profile shown in Table 
2.4.  
 
Table 2.4. Thermal profile of PCR reaction. 
Temperature (ºC) Time Cycle number 
94 2 minutes 1 
94 30 seconds 
2-39 55 1 minute 
72 30 seconds 
4 to 8 Unlimited - 
 
The products of amplification were separated and visualized on a standard 1.5% agarose gel made up 
in 1X TRIS/Borate/EDTA buffer (0.89M Tris-HCl, 0.89M Boric Acid, 0.02M EDTA pH = 8.3) to a final 
volume of 1L deionized water. Syber Safe diluted 10,000X was added to the solution. The molecular 
weight marker used was the 100 bp DNA ladder. Each amplified PCR product (5μL) was loaded and 
electrophoresis was carried out at 100V for 30 minutes. The bands were visualized on the charge-
coupled device (CCD) Camera System LAS 3000 (Fujifilm, Tokyo, Japan). 
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2.4. Culture Characterization by Immunocytochemistry 
The culture media used in the protocol is selective for fibroblast growth. However, other structural 
cells, such as epithelial cells, could growth in these conditions. For this reason, it was necessary to 
analyze the purity of the cultures. Additionally, fibroblasts may differentiate to myofibroblasts. The 
differential expression of structural proteins such as α-smooth muscle actin (sma), vimentin, and 
cytokeratins has been proved to be efficient markers in differentiating myofibroblasts, fibroblasts, and 
epithelial cells, respectively. α-sma is a contractile protein found in the cytoplasm of myofibroblasts, 
but not fibroblasts (Adegboyega et al., 2002). Vimentin is present in myofibroblasts and fibroblasts, but 
not in epithelial cells. Finally, cytokeratins are found in epithelial cells, but not in fibroblasts.  
To perform the experimental protocols, cells cultured in 4-well CultureSlides® were washed three 
times with PBS 1X (prepared from PBS 10X without calcium and magnesium), and fixed with cold 
paraformaldehyde at 4% for 15 minutes at room temperature. Then, cells were washed twice with PBS 
1X, and incubated with a permeabilization solution that contains 0.2% of Triton X-100 in PBS 1X for 10 
minutes at room temperature. The CultureSlides® were then washed twice with PBS 1X and 
incubated with blocking buffer, which consists to 1% bovine serum albumin (BSA) and PBS, for 1 hour 
in order to block non-specific bindings. Then, antibodies against α-sma diluted 1:500, vimentin diluted 
1:100 and pan-cytokeratin (recognizing human cytokeratins 1, 4, 5, 6, 8, 10, 13, 18, and 19) diluted 
1:200 were added for 1 hour at 37ºC. Following that, the slides were washed three times in wash 
buffer. To undertake the detection of the primary antibody the culture slides were incubated with an 
appropriate fluorescent secondary antibody, Alexa Fluor 488, diluted 1:500 for 1 hour.  
The cell nuclei were visualized by DNA staining using 4',6-diamidino-2-phenylindole (DAPI) diluted 
1:10000. Finally, the slides with cultured cells were mounted for microscopy with a watery mounting 
media (ProLong Gold antifade reagent), left to solidify at least 3 hours at room temperature protected 
from the light. Epifluorescence microscopy (Leica Microsystems, Germany) was used to analyze the 
percentage of positive cells on the preparation at 200X magnification. 
 
 
2.5. PGE2 and IL-1β Preparation 
PGE2 and IL-1β were used in this study among the different experimental protocols in order to 
stimulate the cells. PGE2 was dissolved in DMSO to reach a final concentration of 10
-2
M. To 
reconstitute Recombinant Human IL-1β, sterile PBS containing 0.1% BSA was added to the 
commercial vial to prepare the stock solution of 10µg/mL of the pro-inflammatory cytokine. The 
manipulation of each product was performed under sterile conditions to avoid contaminations of cell 
cultures. Cryovials containing PGE2 at 10
-2
M and IL-1β at 10µg/mL were then aliquoted to avoid 
repeated freeze-thaw cycles and stored under sterile conditions at -80ºC. 
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2.6. XTT Assay to Evaluate DMSO Effect 
 
DMSO is a substance that at high concentrations may have cytotoxic effects on cell cultures. Since 
the higher PGE2 concentration used in experimental protocols was 10μM, the maximum concentration 
of DMSO used to dissolve PGE2 was 0.1%.  
The possible toxic effect of this reagent on fibroblasts survival/viability was determined by XTT assay. 
Metabolic active cells reduce the tetrazolium salt (sodium 3’-[1-(phenylamino-carbonyl)-3,4-
tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate) to orange colored compounds of 
formazan. The dye formed is water soluble and the dye intensity can be read at a given wavelength 
with a spectrophotometer. The intensity of the dye is proportional to the number of metabolic active 
cells. Briefly, the viability of cells was checked through microscope observation on a Neubauer 
Chamber by Trypan Blue exclusion. Then, cells were plated in 24-well culture plates (50 000 cells ⁄ 
well) with culture media. Cells were allowed to attach overnight. On the following day, cells were 
growth-arrested by the incubation with serum-free media (SFM) for 24 hours. Then, fibroblasts were 
incubated for additional 24 hours in presence or absence of 0.1% DMSO diluted in SFM. After the 
treatment, XTT mixture was prepared (protecting from the light and under sterile conditions) by mixing 
XTT labeling reagent and electron-coupling reagent according to the instructions of the supplier. The 
cells were washed with sterile PBS 1X and the XTT mixture previously prepared was added to each 
well. The culture plates were incubated at 37ºC, and the absorbance was measured after the 
incubation period (2 and 4 hours) at 490 nanometres (nm) using a microplate spectrophotometer 
(Thermo Multiskan EX). 
 
 
2.7. Experimental Protocols 
It has been reported that COX expression, in response to exogenous stimulus, is more robust in 
quiescent fibroblasts than in proliferating cells. Primary fibroblasts cultured in SFM for 24 – 48h are 
morphologically and biochemically different from those cultured in 10 – 20% serum. These cells are 
considered quiescent (Wu, 2007). Primary human fibroblasts continue to exhibit high metabolic rates 
when induced into quiescence via serum withdrawal. Additionally, most studies have carried out the 
experimental protocols from subconfluent cell cultures. Considering these evidence, to perform the 
various experimental protocols, and in order to compare the results of this study with previous 
published data, the cells were started when cultures were subconfluent and after incubation with SFM 
for 24 hours. For that step, cells were washed once with warm PBS 1X and fresh SFM was added to 
the culture flasks before each experimental protocol.  
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2.7.1. Basal Secretion of PGE2 and Basal Expression of COX Enzymes and EP 
Receptors 
After incubation with SFM for 24 hours, culture supernatants were collected and used to analyze basal 
secretion of PGE2 by means of Enzyme-Linked ImmunoSorbent Assay (ELISA). In order to analyze 
the basal expression of COX enzymes and EP receptors, cell lysates were obtained and used to study 
the basal expression of COX-1, COX-2, EP1, EP2, EP3 and EP4 protein by means of immunoblot 
analysis (Figure 2.2).  
 
 
2.7.2. Effect of IL-1β on PGE2 Secretion and COX Enzymes and EP Receptors 
Expression 
To evaluate the effect of IL-1β on secretion of PGE2 and expression of COX enzymes and EP 
receptors cells were incubated with fresh SFM in the presence of 10ng/mL IL-1β, for different times. 
Supernatants and cells incubated for 24 hours with IL-1β were collected to analyze PGE2 secretion by 
means of ELISA and COX-2 protein expression by means of immunoblot, respectively (Figure 2.2). To 
analyze COX-1, EP1, EP2, EP3, and EP4 expression, by means of immunoblot, the cells were 
stimulated for 72 hours with IL-1β, and cell lysates were collected to each 24 hours (Figure 2.2).  
 
 
2.7.3. Effect of PGE2 on the Expression of COX Enzymes 
To evaluate the effect of PGE2 on the expression of COX enzymes, fibroblasts were incubated with 
fresh SFM in the presence of 1 or 10μM PGE2 during 24 hours and cell lysates were used to analyze 
the expression of COX-1 and COX-2 by means of immunoblot (Figure 2.3). 
 
 
 
 
 
Figure 2.2. Design of the experimental protocols performed to analyze COX-1 and COX-2 enzymes and EP 
receptors expression, and PGE2 secretion. 
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Figure 2.3. Design of the experimental protocols performed to analyze the expression of both COX-1 and COX-2 
enzymes. 
 
 
2.8. ELISA for PGE2 
To measure the secretion of PGE2, culture supernatants were collected and centrifuged at 400g for 10 
minutes at 4ºC, in a refrigerated centrifuge (eppendorf, Centrifuge 5417 R), sterilized through 0.22-µg 
filters, and stored at -80ºC until the measurement. 
The concentration of PGE2 was measured using a specific kit (Prostaglandin E2 EIA Kit – Monoclonal) 
following the manufacturer’s instructions. The assay is based on the principle that in vivo PGE2 is 
rapidly converted into an inactive metabolite (13,14-dihydro-15-keto PGE2) by the PG 15 
dehydrogenase pathway (Granström et al., 1980; Hamberg and Samuelsson, 1971). 
Briefly, the content of one vial of EIA Buffer Concentrate was diluted with 90mL double-distilled water 
(ddH2O). Care was taken to rinse the vial to remove any salts that may have precipitated. The content 
of a 2.5mL vial of Wash Buffer Concentrate was diluted to a total volume of 1L with ddH2O and then 
0.5mL Tween®20 was added. The content of the PGE2 standard was reconstituted with 1mL of EIA 
Buffer and stored at 4ºC. The standard was prepared through serial dilution from 7,8pg/mL to 
1000pg/mL. The PGE2 acetylcholine esterase tracer and the PGE2 monoclonal antibody were both 
reconstituted with 6mL EIA Buffer. To perform the assay, the reagents and 50µL of samples, in 
duplicate, were added to the plate according to the manufacturer’s instructions. The plate was covered 
and incubated for 18 hours at 4 ºC. When the plate was ready to develop, Ellman’s Reagent was 
reconstituted in 20mL ddH2O. The wells of the plate were rinsed 5 times with Wash Buffer before 
adding 200µL Ellman’s Reagent to each well. The plate was re-covered, to protect it from the light, 
placed in a dark box and incubated at room temperature for 60 – 90 minutes on an orbital shaker. 
Once incubated, the plate was read at 405 nm using a microplate spectrophotometer (Thermo 
Multiskan EX). 
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2.9. Immunoblot Analysis 
2.9.1. Preparation of Protein Lysates from Cells 
Following experimental treatments, protein lysates were obtained. Cells were washed three times with 
ice-cold PBS 1X and scrapped in PBS 1X to detach the cells from the surface of the culture flasks. 
Cells were then collected into an appropriate tube and centrifuged at 1500g for 5 minutes at 4ºC 
(eppendorf, Centrifuge 5417 R). The cells were resuspended in 0.4mL of ice cold lysis buffer that 
contains a complete protease inhibitor cocktail tablet in 50mL of 0.05mol/L Hepes buffer solution, 
0.05% v/v Triton X-100 and 625μmol/L phenylmethylsulfonyl fluoride (Pefabloc). The lysates were 
maintained for 20 minutes on ice and then collected and frozen at -80ºC for further utilization.  
When required, the cell suspension was thawed and thereafter sonicated at 35% amplitude in ice, 
twice, for 15 seconds, in a sonifier (Branson Sonifier 250, Danbury, CT, USA) and centrifuged at 
12,000g for 10 minutes, at 4ºC. Supernatant containing protein lysates were then collected and stored 
at -80ºC. 
 
 
2.9.2. Protein Concentration Determination 
To ensure an equal loading in the protocol of immunoblot assay, the amount of protein in cell lysates 
was quantified, using a Protein Assay Kit based on the Lowry method. The kit measures the total 
protein using known BSA concentrations as standard. Briefly, the standards were prepared by the 
dilution of Protein Standard Solution in deionized water to a final volume of 250μL, as shown in Table 
2.5. The blank was prepared adding 250μL of water. Samples were analyzed at 1:50 dilution in water 
and the Lowry Reagent was added and mixed in each tube and left for 20 minutes. After that, the Folin 
& Ciocalteau’s Phenol Reagent Working Solution was added and mixed in each tube to allow colour to 
develop (30 minutes after). The content of each tube was transferred to a 96-well plate and all 
samples were quantified in duplicates and averages were used to perform the quantification. The 
absorbance was measured at 630 nm using a microplate spectrophotometer (Thermo Multiskan EX). 
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Table 2.5. Standards preparation for calibration curve. 
Protein Concentration 
(µg/mL) 
Protein Standard Solution 
(μL) 
Water (μL) 
0 0 250 
50 31.2 218.7 
100 62.5 187.5 
200 125 125 
300 187.5 62.5 
400 250 0 
 
 
2.9.3. Protein Electrophoresis 
Under denaturing conditions, protein samples can be separated according to their size on acrylamide 
gels. Since different proteins with similar molecular weights may migrate differentially due to their 
differences in secondary, tertiary or quaternary structure, sodium dodecyl sulfate (SDS), an anionic 
detergent, is used to reduce proteins to their primary structure, giving nearly a uniform negative 
charge along the length of the polypeptide. The voltage applied, allows the migration of anions and the 
proteins are fractionated by size.  
To undertake the electrophoresis, the NuPAGE system was used. Basically, 15µg of protein extract 
were denatured in the presence of a loading buffer 1:4 ratio (NuPAGE lithium dodecyl sulfate (LDS) 
sample buffer) and NuPAGE sample reducing agent 1:10 ratio at 70ºC for 10 minutes in a 
thermocycler (MJ Research PTC-100, USA). Samples were loaded in 7% TRIS-acetate gels (1.5mm x 
10 well) in SDS Running Buffer (Novex TRIS-Acetate SDS Running Buffer 20X), set in a vertical 
electrophoresis chamber, XCell Sure Lock Mini-Cell (Invitrogen). To maintain proteins in a reduced 
state, during protein gel electrophoresis, 500µL of an antioxidant (NuPAGE) was added to the running 
buffer. A molecular weight marker (SeeBlue Plus2 Pre-Stained Standard) was loaded on the gel as a 
size reference. This marker provides an easier band identification, since it indicates the molecular 
weight in kilodalton (kDa) of the proteins and allows a quickly evaluation of the transfer efficiency. 
Proteins were separated at 125V for 90 minutes using an external power source, BioRad Power Pac 
1000 (BioRad Laboratories Ltd., Hemel Hemstead, UK), until the dye had run to the bottom of the gel.  
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2.9.4. Blotting 
The proteins were transferred using a dry blotting system (iBlot® Dry Blotting System, Invitrogen). This 
system blots proteins from polyacrylamide gels in 7 minutes and any additional buffers or external 
power supply are needed. The iBlot uses disposable stacks and the bottom stack includes an 
integrated 0.2µm nitrocellulose membrane. The order of layers in the transfer system was from bottom 
to top: anode stack with a nitrocellulose membrane incorporated, acrylamide gel, filter paper, cathode 
stack and disposable sponge.   
 
 
2.9.5. Blocking 
After transfer and in order to block nonspecific binding sites the membranes were placed in a blocking 
buffer that contains 5% nonfat dry milk and 0.1% Tween®20 in 10nmol/L PBS for 1 hour at room 
temperature. This and further steps were performed carefully with gentle shaking in an orbital shaker 
(Stuart Scientific SO3 Orbital Shaker, UK).  
 
 
2.9.6. Antibodies Incubation 
Membranes were incubated with the primary antibody against COX-1, COX-2, EP1, EP2, EP3 or EP4 
diluted 1:1000 in blocking buffer overnight at 4ºC. Membranes were washed four times in an orbital 
shaker with wash buffer (0.5% Tween®20 in 10nmol/L PBS) and incubated with specific horseradish 
peroxidase-labeled secondary antibodies: goat anti-rabbit (EP1, EP2 and EP3), goat anti-mouse 
(COX-2), or donkey anti-goat (COX-1 and EP4) diluted 1:3000 in blocking buffer at room temperature 
for 2 hours. Then, the membranes were washed four times in wash buffer.  
For β-actin protein detection, membranes were incubated with a monoclonal anti- β-actin antibody 
diluted 1:10000 in blocking buffer, overnight at 4ºC, washed four times with wash buffer and incubated 
with the appropriate peroxidase-conjugated goat anti-mouse diluted 1:10000 in blocking buffer at room 
temperature for 2 hours.   
 
 
2.9.7. Detection System 
Immunoreactive bands were visualized by using a chemiluminescent method, which emits light and 
allows the visualization of the proteins on the membranes. To perform this step the membranes were 
incubated for 5 minutes with the commercial Supersignal West Pico Chemiluminescent Substrate and 
the bands were detected with the CCD Camera System LAS 3000 (Fujifilm, Tokyo, Japan). Band 
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intensities were quantified with Fujifilm Image Gauge v.4.0 Software and normalized to intensities of β-
actin and assessed from the same samples.   
 
 
2.9.8. Stripping of the Membranes 
Membranes were stripped to remove previously bound antibodies. This step enables detection of 
other proteins in the same membrane. Briefly, the membranes were washed to remove 
chemiluminescent substrate and incubated for 15 minutes with the commercial Restore Western Blot 
Stripping Buffer, at room temperature in an orbital shaker and protected from the light. After this time, 
the membranes were washed in wash buffer and blocked for 1 hour prior the addition of the first 
antibody.  
 
 
2.10. Statistical Analysis 
In order to perform the statistical analysis of the results, the statistical software SPSS 18.0 was used. 
Immunofluorescence data are expressed as medians (25
th
 – 75
th 
interquartiles) of positive-cell 
percentage among total cells. ELISA results are shown as medians (25
th 
– 75
th 
interquartiles) of 
picograms of PG per micrograms of total proteins contained in each flask. Immunoblot results are 
expressed as medians (25
th 
– 75
th 
percentiles) of band intensities normalized for β-actin. The non-
parametric statistical Mann-Whitney U test was used for between-group comparisons, and the 
Wilcoxon rank test was used for paired comparisons after confirming differences with the Friedman 
test. Statistical significance was set at a p value of less than 0.05. Graphic representation of the 
results was performed using the scientific 2D graphing and statistics software GraphPad Prism 5.0 
(GraphPad Software Inc., San Diego, California, USA). 
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3. Results 
3.1. Mycoplasma PCR Test 
The PCR reaction assay was performed in order to exclude mycoplasma contaminations of cell 
cultures, to guarantee the quality and purity of samples used in the protocols. The weak band at 192 
bp visualized in lanes 4 to 14 that include the cell culture samples, corresponds to the internal PCR 
amplification control, which indicates an effective PCR process, and discards contaminations by 
mycoplasma. On the other hand, the strong band at 270 bp also presented in the agarose gel and 
observed in lane 2 corresponds to the positive control and demonstrates an effective amplification of 
the mycoplasma product by the PCR process. Furthermore, in order to confirm the reliability of the 
procedure, the negative controls were performed with and without an internal PCR amplification 
control, observed in the lanes 1 and 3, respectively. None of cultures used in experimental protocols 
were found to be positive for mycoplasma.  
The Figure 3.1 shows an example of mycoplasma analysis.  
 
 
 
Figure 3.1. Representative agarose gel obtained from the DNA screening of mycoplasma by PCR. The presence 
of mycoplasma contamination produces a fragment of 270bp and the internal control generates a band of 192 bp. 
The PCR products were separated on a 1.5% agarose gel containing 10,000X dilution of Syber Safe and 
visualized with CCD Camera System LAS 3000. MW: molecular weight (standard 100 bp DNA ladder); 1: 
negative control (sterile de-ionized water) with internal PCR amplification control (192 bp); 2: positive control 
(DNA fragments of Mycoplasma orale genome, 270 bp); 3: negative control without internal PCR amplification 
control; 4-14: samples from fibroblast cultures with internal PCR amplification control (192 bp). 
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3.2. Culture Characterization 
In order to test the purity of fibroblast cultures, the immunocytochemistry technique was performed. 
The representative images obtained from immunofluorescence analysis are presented in Figures 3.2, 
3.3, 3.4. and 3.5. Cultures of control-NM, NM-AIA, NP-AT, NP-AIA, control-BM, and BM-AIA cells 
incubated with culture media for 24 hours did not contain cytokeratin-positive cells (Figure 3.3), 
whereas all cells were positive for vimentin (Figure 3.2). Myofibroblasts were also present in the cell 
cultures, since there were cells positive to α-sma (Figure 3.5). However, no significant differences 
were observed in the myofibroblast percentage in the different cell cultures (control-NM = 1.6%; 1.3-
3.3, NM-AIA = 3.5%; 2.0-3.6, NP-AT = 4.7%; 2.4-8.7, NP-AIA = 4.5%; 2.2-5.7, control-BM = 1.5%; 1.3-
3.0, BM-AIA = 2.1%; 1.9-2.7). 
 
 
 
 
 
 
 
 
 
Figure 3.2. Representative image from immunofluorescence analysis of quiescent control-NM fibroblasts, 
indicating the presence of vimentin fibers. The presence of vimentin fibers (green fibers) in the cytoplasma of 
quiescent cells, confirms the fibroblast phenotype of cells in culture. The cell nuclei were visualized by DNA 
staining using DAPI diluted 1:10000 and epiflluorescence microscopy was performed to analyze the positive cells 
on preparation (original magnification 200X). 
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Figure 3.3. Representative image from immunofluorescence analysis of quiescent control-NM fibroblasts, 
indicating the total absence of cytokeratins. The total absence of immunofluorescent staining for cytokeratins 
demonstrates de lack of epithelial cells. The cell nuclei were visualized by DNA staining using DAPI diluted 
1:10000 and epiflluorescence microscopy was performed to analyze the positive cells on preparation (original 
magnification 200X). 
 
 
 
 
 
 
Figure 3.4. Representative image from immunofluorescence analysis of NM epithelial cells, indicating the 
presence of cytokeratins. The presence of immunoflorescent staining for cytokeratins confirms the epithelial 
phenotype of cells in culture (positive control). The cell nuclei were visualized by DNA staining using DAPI diluted 
1:10000 and epiflluorescence microscopy was performed to analyze the positive cells on preparation (original 
magnification 200X). 
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Figure 3.5. Representative image from immunofluorescence analysis of quiescent control-NM fibroblasts, 
indicating the presence of α-sma. The detection of α-sma confirms the presence of myofibroblasts in the cell 
cultures. The cell nuclei were visualized by DNA staining using DAPI diluted 1:10000 and epiflluorescence 
microscopy was performed to analyze the positive cells on preparation (original magnification 200X). 
 
 
3.3. DMSO Effect on Fibroblast Cultures 
The results obtained from the XTT assay demonstrated that 0.1% DMSO (maximum concentration 
used to dissolve PGE2) did not cause any significant effect on fibroblasts viability after 24 hours of 
incubation with the reagent, when compared with control media (non-stimulated cells). 
 
 
3.4. PGE2 Secretion 
The quiescent fibroblasts were incubated with culture media in the presence or absence of 10ng/mL 
IL-1β for 24 hours, and PGE2 secretion was analyzed in culture supernatants by means of ELISA.  
 
At baseline, the secretion of PGE2 was low and no statistical differences were found in the secretion of 
PGE2 when the different fibroblast cultures were compared. However, the incubation with IL-1β for 24 
hours significantly increased the ratio of PGE2/total protein in control-NM, NP-AIA, control-BM, and 
BM-AIA, with no effect in NM-AIA. There were no differences in the IL-1β-induced secretion of PGE2 
among fibroblasts from control-NM, control-BM, and AIA-BM. However, the ratio of PGE2/total protein 
was significantly lower in cells from NP-AIA and NM-AIA compared to control-NM, control-BM and BM-
AIA cells (Figure 3.6).  
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Figure 3.6. Effect of IL-1β on PGE2 protein secretion. Quiescent fibroblasts from control-NM (n = 7), control-BM 
(n = 5), NM-AIA (n = 4), NP-AIA (n = 7), and BM-AIA (n = 3) were incubated with or without 10ng/mL IL-1β for 24 
hours. The secretion of PGE2 was measured by means of ELISA. The figure shows the significant differences in 
the secretion of PGE2 between the different tissues and after incubation with IL-1β. * p < 0.05 compared with 
control media.  
 
 
3.5. COX Expression 
3.5.1. Basal Expression of COX Enzymes 
The basal expression of COX-1 protein was measured in quiescent fibroblasts incubated with control 
media for 24 hours. By means of immunoblot analysis, the results demonstrated that COX-1 protein 
expression was not different in upper airways (control-NM, NM-AIA, NP-AT, and NP-AIA). Similarly, in 
lower airways, no differences were found when fibroblasts from control-BM and BM-AIA were 
compared. However, the comparison between upper and lower airways shows that in fibroblasts from 
BM of control subjects, the COX-1 protein expression was higher compared to the respective control-
NM. Additionally, in patients who suffer from AIA, COX-1 protein expression was higher in fibroblasts 
from BM when compared with the respective NM and NP (Figure 3.7).  
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The basal expression of COX-2 was also analyzed in all fibroblast cultures. However, the expression 
of the protein was not detected in any fibroblast cultures, probably because COX-2 is an inducible 
enzyme only induced under inflammatory conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. COX-1 basal expression on cultured fibroblasts. Quiescent fibroblasts from control-NM (n = 3), 
control-BM (n = 5), NP-AT (n = 3), NM-AIA (n = 4), NP-AIA (n = 4), and BM-AIA (n = 5) were incubated for 24 
hours with SFM. A, COX-1 protein expression analyzed by means of immunoblotting. B, Representative 
immunoblots of COX-1 and corresponding β-actin. The molecular weight of each protein is also represented. * p < 
0.05 compared with both control-NM and NM-AIA (COX-1/ β-actin ratio = 1). † p < 0.05 compared with both NP-
AT and NP-AIA.  
 
 
3.5.2. Effect of IL-1β on COX Expression 
COX-1 is considered normally a non-inducible enzyme. Although, increases in its expression has been 
found under inflammatory conditions (Roca-Ferrer et al., 2011). Thus, in order to evaluate the effect of 
10ng/mL IL-1β on COX-1 protein expression, quiescent fibroblasts were incubated with the pro-
inflammatory cytokine and COX-1 expression was measured at 24, 48, and 72 hours.  
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In control-NM fibroblasts, IL-1β at 10ng/mL significantly induced COX-1 protein expression at 24, 48, 
and 72 hours, compared with cells incubated with culture media. On the other hand, IL-1β had no 
effect on COX-1 protein expression in fibroblasts from NP-AT, NM-AIA, and NP-AIA tissues, when 
compared with the respective cells incubated with culture media (Figure 3.8A and B).   
Additionally, compared with IL-1β treated control-NM fibroblasts, expression of COX-1 was 
significantly lower in fibroblasts from NM-AIA, NP-AIA, and NP-AT at 24 hours (NP-AIA = 1.01; 0.87-
1.14), 48 hours (NM-AIA = 0.85; 0.58-1.02 and NP-AIA = 1.00; 0.87-1.14), and 72 hours (NM-AIA = 
0.92; 0.68-1.14, NP-AT = 1.01; 0.76-1.54, and NP-AIA = 0.80; 0.64-0.98).  
When COX-1 protein expression was analyzed in bronchial fibroblasts, the results were unclear. In 
fibroblasts from both BM (control and AIA), the results suggest an increase on COX-1 protein 
expression after stimulation with IL-1β at 10ng/mL (Figure 3.8C) over the time, but no differences were 
found in these tissues when statistical analysis was performed. In this case the variability of the results 
and the reduced number of samples (n = 3) available to undertake the experimental protocols failed to 
demonstrate any differences in the expression levels of COX-1 protein in fibroblasts from both control-
BM and BM-AIA. 
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Figure 3.8. Effect of IL-1β on COX-1 expression. Fibroblasts from control-NM (n = 9), NP-AT (n = 9), NM-AIA (n = 
6), and NP-AIA (n = 10) were incubated with 10ng/mL IL-1β for 72 hours. A, COX-1 protein expression in 
quiescent fibroblasts from control-NM (black circle), NM-AIA (white circle), NP-AT (black triangles), NP-AIA (white 
triangles) was analyzed by means of immunoblotting. B, Representative immunoblot of control-NM, showing the 
time-dependent increase of COX-1 protein expression. C, Representative immunoblot of both control-BM and 
BM-AIA, showing the slight time-dependent increase in COX-1 protein expression. The molecular weight of each 
protein is also represented. * p < 0.05 compared with control media (COX-1/β-actin ratio = 1). # p < 0.05 
compared with control-NM fibroblasts incubated with IL-1β.  
 
In order to evaluate the effect of 10ng/mL IL-1β on COX-2 expression, fibroblasts were incubated with 
the pro-inflammatory cytokine and the COX-2 expression was measured at 24 hours by means of 
immunoblot. Compared with control-NM incubated with IL-1β, the expression of COX-2 was 
significantly increased in fibroblasts from control-BM (2.48; 1.97-6.26) and BM-AIA (3.15; 2.45-3.96) 
and significantly decreased in fibroblasts from NP-AIA (0.01; 0.00-0.03). The lowest ratio COX-2/β-
actin was verified in fibroblasts from NP-AIA, since the values were significantly lower from those 
obtained for all other tissues under analysis (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 24 48 72
BM-AIA
COX-1
β-actin
Time (hours)0 24 48 72
Control-BM
COX-1
β-actin
Time (hours)
C 
70kDa 
43kDa 
Results 
41 
 
5
4
3
2
0
NMNM NP
1
BMBM
Control AIA
7
6
*
*
*
p = 0.048
p = 0.004
p = 0.024
p = 0.036
p = 0.032
p = 0.036
R
a
ti
o
 C
O
X
-2
/β
-a
c
ti
n
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Effect of IL-1β on COX-2 expression. Quiescent fibroblasts from control-NM (n = 6), control-BM (n = 
3), NM-AIA (n = 4), NP-AIA (n = 5), and BM-AIA (n = 3) were incubated with 10ng/mL IL-1β for 24 hours. * p < 
0.05 compared with control-NM fibroblasts.  
 
 
3.5.3. Effect of PGE2 on COX Expression 
To evaluate the effect of PGE2 in both COX-1 and COX-2 protein expression, quiescent fibroblasts 
from control-NM, NP-AT, control-BM, NM-AIA, NP-AIA, and BM-AIA, were incubated with SFM in the 
absence or presence of 1 or 10μM PGE2 for 24 hours. Compared with cells incubated with culture 
media, COX-1 protein expression was significantly increased in fibroblasts from control-NM (1μM = 
1.67; 1.44-2.27, 10μM = 1.99; 1.74-3.48), NM-AIA (1μM = 1.61; 1.33-2.45, 10μM = 1.97; 1.52-3.76), 
NP-AT (1μM = 1.49; 1.28-2.35, 10μM = 2.55; 1.81-3.98), and NP-AIA (1μM = 1.22; 1.06-2.15, 10μM = 
1.38; 1.14-2.27) when cells were incubated with 1 or 10μM PGE2 (Figure 3.10A and B). No statistical 
differences were found when the different fibroblast cultures were compared.  
The effect of PGE2 on COX-1 protein expression was also evaluated in cultured fibroblasts from both 
control-BM and BM-AIA. In these samples the stimulation of fibroblasts with 1 or 10μM PGE2 appears 
to increase the expression of COX-1, such as occurred in fibroblasts from upper airways samples 
(Figure 3.10B). However, the slight increase found in the expression of COX-1 in these tissues was 
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not statistically significant, probably due to the low number of samples (n = 3) available to perform the 
experimental protocols.   
Additionally, the effect of PGE2 on COX-2 protein expression was analyzed. In contrast to the effect 
found in COX-1 expression, PGE2 did not stimulate the expression of COX-2 in any fibroblast cultures. 
The Figure 3.10C shows a representative immunoblot performed from the same samples used to 
analyze COX-1 protein expression. The absence of bands in the immunoblot assay clearly 
demonstrates the lack of detection of COX-2 protein expression when fibroblasts were stimulated with 
PGE2 at different concentrations.  
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Figure 3.10. Effect of PGE2 on COX enzymes expression. Quiescent fibroblasts from control-NM (n = 10), NM-
AIA (n = 7), NP-AT (n = 6), NP-AIA (n = 9), control-BM (n = 3), and BM-AIA (n = 3) were incubated with or without 
1 or 10μM PGE2 for 24 hours. A, COX-1 protein expression analyzed by means of immunoblotting. B, 
Representative immunoblot of control-NM, NM-AIA, NP-AT, NP-AIA, control-BM, and BM-AIA, showing the 
concentration-dependent increase of COX-1 protein expression. C, Representative immunoblot of control-NM 
(same samples used to evaluate COX-1 protein expression), showing the lack of COX-2 protein expression. The 
molecular weight of each protein is also represented. * p < 0.05 compared with respective control media (COX-
1/β-actin ratio = 1).  
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3.6. EP Receptors Expression 
3.6.1. Basal Expression of EP Receptors 
To evaluate the basal expression of EP receptor subtypes (EP1 – EP4), quiescent fibroblasts were 
incubated with SFM for 24 hours and expression of proteins was measured by means of immunoblot 
analysis. The EP1 receptor has a molecular weight of 41 kDa, approximately. When the results 
obtained from immunoblot were analyzed, non-specific bands were observed on the membranes. 
Since the molecular weight of these bands did not correspond to the molecular weight of the EP1 
receptor, it was not possible evaluate the basal expression of EP1 receptor in fibroblasts from control-
NM, NM-AIA, NP-AT, NP-AIA, control-BM, and BM-AIA tissues. On the other hand, the baseline 
expression of EP2, EP3, and EP4 receptors was measured, and the results obtained from statistical 
analysis are show in Table 3.1. 
EP2 protein expression was found in all fibroblast cultures. At baseline, there were no differences in 
EP2 protein expression when fibroblasts from control-NM and NM-AIA were compared. However, 
compared to control-NM, the basal expression of EP2 in fibroblasts from NP-AT was significantly 
higher. In addition, the expression of EP2 in fibroblasts from NP-AIA was significantly lower compared 
with both control-NM and NP-AT (Figure 3.11).   
On the other hand, there were no differences in EP3 protein expression when comparing fibroblasts 
from control-NM with fibroblasts from NP-AIA. However, the EP3 expression was significantly lower in 
fibroblasts from NP-AT and NM-AIA tissues, when comparing with both control-NM and NP-AIA. 
Additionally, the basal expression of EP3 in fibroblasts from NM-AIA was significantly lower compared 
with both NP-AT and NP-AIA (Figure 3.12).  
At baseline, there were no significant differences in the expression of EP4 in cultured fibroblasts from 
control-NM, NM-AIA, and NP-AT. Nevertheless, it was observed a higher expression of this receptor 
among cells from NP-AIA tissue, which was significantly different, when compared with control-NM, 
NM-AIA, and NP-AT (Figure 3.13).  
The basal expression of the EP receptors was also measured in cultured fibroblasts from both BM 
(control and AIA). The results were not represented in the Table 3.1., since the number of samples 
available to perform the protocols was too small. Moreover, the results showed a great variability. 
However, when the statistical analysis was performed, differences in the expression of EP3 and EP4 
receptors were found, but not in EP2 receptor. At baseline, the expression of EP3 seems to be lower 
in fibroblasts from control-BM when compared with control-NM and both NP-AT and NP-AIA (Figure 
3.12B). Considering the baseline expression of EP4 receptor, the results demonstrated that this 
receptor could be lower in fibroblasts from control-BM, when compared to NP-AIA, as was verified for 
the other tissues (Figure 3.13B). 
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Table 3.1. Baseline levels of EP receptors in cultured fibroblasts. 
EP receptor Control-NM (n=7) NM-AIA (n=8) NP-AT (n=9) NP-AIA (n=6) 
EP1 Not detected Not detected Not detected Not detected 
EP2 
1.07 
(0.87-1.56) 
1.22 
(0.21-2.14) 
1.18* 
(1.14-2.72)  
0.67 *† 
(0.18-0.93)  
EP3 
2.60 
(0.75-4.03) 
0.49* 
(0.31-0.55) 
0.65 *‡ 
(0.62-0.77) 
1.41 ‡† 
(1.30-1.70) 
EP4 
0.34 
(0.27-0.54) 
0.87 
(0.25-1.16) 
0.44 
(0.34-0.70) 
1.64 *‡† 
(1.18-2.21)  
The results are expressed as medians (25
th
 to 75
th
 interquartiles) of the EP receptor/β-actin ratio. The Mann-
Whitney U test was used for comparisons between groups. * p < 0.05 compared with control-NM. ‡ p < 0.05 
compared with NM-AIA. † p < 0.05 compared with NP-AT.  
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Figure 3.11. Basal expression of EP2 receptor on cultured fibroblasts. Quiescent fibroblasts from control-NM (n = 
7), NM-AIA (n = 8), NP-AT (n = 9), NP-AIA (n = 6), control-BM (n = 4), and BM-AIA (n = 4) were incubated for 24 
hours with SFM. A, EP2 protein expression analyzed by means of immunoblotting. B, Representative immunoblot 
of control-NM, NP-AT, NM-AIA, and NP-AIA, showing the differences between tissues. The molecular weight of 
each protein is also represented. * p < 0.05 compared with control-NM. † p < 0.05 compared with NP-AT. 
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Figure 3.12. Basal expression of EP3 receptor on cultured fibroblasts. Quiescent fibroblasts from control-NM (n = 
7), NM-AIA (n = 8), NP-AT (n = 9), NP-AIA (n = 6), control-BM (n = 4), and BM-AIA (n = 4) were incubated for 24 
hours with SFM. A, EP3 protein expression analyzed by means of immunoblotting. B, Representative immunoblot 
of control-NM, control-BM, NP-AT, NM-AIA, and NP-AIA, showing the differences between tissues. The molecular 
weight of each protein is also represented.  * p < 0.05 compared with control-NM. ‡ p < 0.05 compared with NM-
AIA. † p < 0.05 compared with NP-AT. 
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Figure 3.13. Basal expression of EP4 receptor on cultured fibroblasts. Quiescent fibroblasts from control-NM (n = 
7), NM-AIA (n = 8), NP-AT (n = 9), NP-AIA (n = 6), control-BM (n = 4), and BM-AIA (n = 4) were incubated for 24 
hours with SFM. A, EP4 protein expression analyzed by means of immunoblotting. B, Representative immunoblot 
of control-NM, control-BM, NP-AT, NM-AIA, and NP-AIA, showing the differences between tissues. The molecular 
weight of each protein is also represented. * p < 0.05 compared with control-NM. ‡ p < 0.05 compared with NM-
AIA. † p < 0.05 compared with NP-AT. 
 
 
3.6.2. Effect of IL-1β on EP Receptors Expression 
In order to evaluate the effect of IL-1β on EP receptors expression (EP1 – EP4), quiescent fibroblasts 
were incubated with or without the cytokine and EP protein expression was measured by means of 
immunoblot at 0, 24, 48, and 72 hours. As seen in basal expression of EP receptors, it was not 
possible to detect EP1 receptor when cultured fibroblasts were stimulated with 10ng/mL IL-1β for 72 
hours.  
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The EP2 protein expression increased significantly in control-NM and NP-AT when fibroblasts were 
incubated with 10ng/mL IL-1β at 24 (NP-AT = 1.40; 1.30-1.62), 48 (control-NM = 1.87; 1.29-2.67, NP-
AT = 1.50; 1.19-2.05), and 72 hours (control-NM = 3.66; 1.61-4.25, NP-AT = 1.86; 1.45-2.26), when 
compared with the respective control media (Figure 3.14A). The expression of EP2 receptor in 
fibroblasts from control-NM increased as early as 24 hours (control-NM = 2.02; 1.17-2.63), when cells 
were stimulated with IL-1β, but this increase was not statistically significant (p = 0.06) (Figure 3.14B). 
The stimulation of fibroblasts with 10ng/mL IL-1β did not increase the expression of EP2 in fibroblasts 
from NM-AIA and NP-AIA, when comparing with control media. Additionally, at 72 hours, the 
expression of EP2 receptor was significantly lower in fibroblasts from NP-AIA tissue (NP-AIA = 1.16; 
0.78-1.99), when compared with control-NM (Figure 3.14A).  
The expression of EP3 was significantly increased in cultured fibroblasts from NP-AIA incubated with 
10ng/mL IL-1β at 48 (NP-AIA = 1.38; 1.13-1.60) and 72 (NP-AIA = 1.37; 0.95-1.79) hours, when 
comparing with the respective control media. Besides, the expression of EP3 receptor was also 
significantly increased in fibroblasts from NP-AIA tissue at 24 and 48 hours, when compared with 
control-NM (control-NM at 24 hours = 0.91; 0.77-1.11, control-NM at 48 hours = 0.82;0.71-1.37). The 
incubation of fibroblasts from control-NM, NM-AIA, and NP-AT with IL-1β did not alter the expression 
of EP3 receptor (Figure 3.15A and B). 
Relatively to the EP4 receptor, the results show that the incubation of fibroblasts with 10ng/mL IL-1β 
did not change the expression of EP4 in any fibroblast cultures.  
The effect of IL-1β on the expression of EP receptors was also evaluated in fibroblasts from both 
control-BM and BM-AIA. The results demonstrate that in these cells the stimulation with the pro-
inflammatory cytokine doesn’t appears to modify the expression of any receptors (EP2, EP3 or EP4).  
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Figure 3.14. Effect of IL-1β on EP2 protein expression. Quiescent fibroblasts from control-NM (n = 7), NP-AT (n = 
9), NM-AIA (n = 4), and NP-AIA (n = 9) were incubated with 10ng/mL IL-1β for 72 hours. A, EP2 expression in 
fibroblasts from control-NM (black circle), NM-AIA (white circle), NP-AT (black triangles), and NP-AIA (white 
triangles) was analyzed by means of immunoblotting. B, Representative immunoblots of control-NM and NP-AT 
showing the time-dependent increase in EP2 expression. The molecular weight of each protein is also 
represented. * p < 0.05 compared with control media (EP2/β-actin ratio = 1). # p < 0.05 compared with control-NM 
fibroblasts incubated with IL-1β.  
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Figure 3.15. Effect of IL-1β on EP3 protein expression. Quiescent fibroblasts from control-NM (n = 8), NP-AT (n = 
7), NM-AIA (n = 4), and NP-AIA (n = 10) were incubated with 10ng/mL IL-1β for 72 hours. A, EP3 expression in 
fibroblasts from control-NM (black circle), NM-AIA (white circle), NP-AT (black triangles), and NP-AIA (white 
triangles) was analyzed by means of immunoblotting. B, Representative immunoblot of NP-AIA showing the time-
dependent increase in EP3 expression. The molecular weight of each protein is also represented. * p < 0.05 
compared with control media (EP3/β-actin ratio = 1). # p < 0.05 compared with control-NM fibroblasts incubated 
with IL-1β.  
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4. Discussion 
According to the recent concept of “united airways” (also known as “one airway, one disease”), 
inflammatory processes of the upper and lower airways often coexist and share some mechanisms 
(Guilemany et al., 2008). Effectively, the histology and physiology of the upper and lower respiratory 
tracts show many similarities and some differences. In addition, the inflammatory diseases that affect 
the upper airways (rhinitis and sinusitis) share some common physiopathological mechanisms with 
those affecting the lower airways (asthma). In this study, it was investigated the different components 
of the COX pathway, as the secretion of PGE2 and the expression of both COX enzymes and also the 
expression of EP1 through EP4 receptors in cultured fibroblasts isolated from NM and NP (upper 
airways) and BM (lower airways) tissues from patients without asthma who are tolerant to aspirin, 
patients with asthma who are intolerant to aspirin, and control subjects. The main objective of this 
investigation was to establish a comparison between the upper and lower airways of these subjects, 
and to verify if there are differences between them, to contribute for a best understanding of the 
metabolism of AA through the COX pathway, and the possible abnormalities that are present at this 
level.  
The main findings of this study are: 1) IL-1β stimulation markedly increased the release of PGE2 in 
fibroblasts from control-NM, control-BM, and BM-AIA. Additionally, IL-1β has a much less stimulatory 
effect in NP-AIA samples and non-significant effect on NM-AIA samples. 2) Stimulation of fibroblasts 
with IL-1β increased the expression of COX-2 in both BM samples (control and AIA). However, the 
expression of COX-2 in stimulated fibroblasts from NP-AIA samples was almost undetectable. 3) The 
baseline levels of COX-1 were higher in both BM samples (control and AIA) compared with upper 
airways. 4) Stimulation of fibroblasts with IL-1β increased the expression of COX-1 in control-NM, but 
not in stimulated fibroblasts from NM-AIA, NP-AT and NP-AIA. 5) Stimulation of fibroblasts with PGE2 
increased the expression of COX-1 in all tissues from upper airways, without significant differences. 6) 
The expression level of the EP2 receptor was low in fibroblasts from NP-AIA, while it was high in 
fibroblasts isolated from NP-AT tissues. 7) The expression of EP3 was low in fibroblasts from NP-AT 
and NM-AIA tissues, and high in fibroblasts from NP-AIA, after stimulation with IL-1β. 8) The 
expression of EP4 receptor was increased in fibroblasts from NP-AIA tissues.  
 
 
4.1. PGE2 Secretion 
PGE2 seems to play an important role in inflammatory processes. This prostanoid is commonly 
considered a potent pro-inflammatory mediator, but in the lungs PGE2 exerts several anti-inflammatory 
and anti-fibrotic effects, that include, for instance, attenuation of eosinophil infiltration, reduction of 
Cys-LTs release, inhibition of fibroblast proliferation, myofibroblast transformation and collagen 
synthesis (Vancheri et al., 2004). In the present investigation, it was reported a markedly increase in 
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the secretion of PGE2 in fibroblasts from control-NM, control-BM, and BM-AIA, after cell incubation 
with a pro-inflammatory cytokine (IL-1β), for 24 hours. Moreover, the cytokine had a slight, but 
significant effect, in the secretion of PGE2 in fibroblasts from NP-AIA tissues. This last result is in 
agreement with previous studies that demonstrated decreased production of PGE2 in NPs, which is 
more accentuated in NPs of patients who suffer from AIA. Altered secretion of PGE2 is a characteristic 
of NPs and AIA and is probably due to an abnormal regulation of the AA pathway in patients with NPs 
especially among those with AIA (Yoshimura et al., 2008; Pérez-Novo et al., 2005; Pierzchalska et al., 
2003). However, it seems to exist some contradictory results when PGE2 secretion is analyzed: in vitro 
studies have demonstrated reduced secretion of PGE2 in several cell types (Jedrzejczak-Czechowicz 
et al., 2008; Pierzchalska et al., 2003; Kowalski et al., 2000), but in vivo studies reported discrepant 
results, with high, similar or lower levels of PGE2 in nasal or bronchoalveolar fluids from patients who 
suffer from AIA, compared with AT asthmatic patients or control subjects (Gyllfors et al., 2003; 
Langmack and Wenzel, 1998; Szczeklik et al., 1996; Picado et al., 1992). In BM of patients who suffer 
from AIA, the production of PGE2 is not altered, and the values observed at this level are similar to 
those found in NM or BM of control subjects, after stimulation with the pro-inflammatory cytokine. 
Effectively there is an altered production of PGE2 in upper airways, but this alteration was not verified 
in lower airways. As previously described, polyps are inflammatory structures that are never seen in 
the lower airways. On the basis of these observations, the differential secretion of PGE2 in upper and 
lower airways can be related with the presence or absence of polyps, i.e, can be involved in the 
pathogenesis of nasal polyposis.  
 
 
4.2. COX Enzymes Expression 
The induction of COX-2 under inflammatory conditions leads to the synthesis of several PGs, and one 
of them is the PGE2 (Baigent and Patrono, 2003). Studies that investigate the expression of COX-2 
show some discrepancies and Pujols et al reported that the differences between publications may be 
due to the study methods (methodology used to perform the experiments and technical limitations of 
some experimental protocols) (Pujols et al., 2004). In this study, it was reported that the stimulation of 
fibroblasts with a pro-inflammatory cytokine, for 24 hours, increased the expression of COX-2 in both 
BM (control and AIA) without differences, when comparing with control-NM. Moreover, in the same 
conditions, the expression of COX-2 in fibroblasts from NP-AIA is almost undetectable. This last result 
is in agreement with previous studies that observed either reduced levels of COX-2 mRNA in NPs, 
especially in patients who suffer from AIA (Pujols et al., 2004) and reduced levels of COX-2 protein in 
fibroblasts from NP-AIA tissues (Roca-Ferrer et al., 2011). The increased expression of COX-2 
verified in lower airways of control subjects and patients who suffer from AIA might contribute to the 
high secretion of PGE2 observed in the lungs, since COX-2 is the major source to the production of 
PGE2. Considering that, and the results reported for PGE2 in this investigation, the COX pathway 
seems to be differentially regulated when upper and lower airways are compared, and in lower 
airways the presence of aspirin intolerance does not modify the expression of COX-2 or the secretion 
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of PGE2, since the levels in both control individuals and patients who suffer from AIA were not 
different.  
COX-1 is considered an enzyme with a constitutive expression in a broad range of cells and tissues, 
where it mediates the synthesis of PGs required for physiological functions. Although COX-1 responds 
to the physiological needs of cells, this enzyme is not considered to be involved in inflammatory 
responses (Simmons et al., 2004). Some studies found an altered expression of this enzyme in 
airways of patients with aspirin sensitivity (Pierzchalska et al., 2007; Pujols et al, 2004; Pierzchalska et 
al., 2003), and other did not report any differences (Picado et al., 1999). Since the knowledge about 
the expression of COX-1 enzyme is very limited and little is known about its regulation, the basal 
expression of COX-1 was analyzed in this study. At baseline, there were no differences between 
patients with or without aspirin sensitivity and control subjects, but it was reported higher levels of 
COX-1 in both BM (control and AIA) without differences, when compared with upper airways. 
Considering these results, it was demonstrated that COX-1 has a differential regulation in upper and 
lower airways and the aspirin sensitivity does not appears to be a factor that alters the regulation of 
the COX-1 enzyme in lower airways, since the expression of COX-1 was not different between control 
subjects and patients who suffer from AIA, in fibroblasts from both BM. 
Some studies reported small increases in the expression of COX-1 in inflamed tissues (McAdam et al., 
2000). For instance, in NPs from patients with CRS associated with cystic fibrosis COX-1 was 
reported to be up-regulated, indicating that airway COX-1 is sensitive to inflammatory stimuli (Roca-
Ferrer et al., 2006). Unfortunately, studies that measured expression of COX-1 in both control-NM and 
NPs of patients with or without aspirin intolerance showed contradictory results: some did not found 
any differences in COX-1 expression between NM and NPs (Adamjee et al., 2006; Picado et al., 
1999), but others found higher levels of this enzyme in NPs from patients with AIA compared with 
control subjects (Pujols et al., 2004). In bronchial epithelial cells from asthmatic patients and control 
subjects it was reported lower levels of COX-1 mRNA in asthmatic patients, and this abnormal event is 
even more accentuated in patients with AIA (Pierzchalska et al., 2007). Previous studies found a delay 
between transcription of mRNA and increased levels of COX-1 protein (Bunimov et al., 2007; Kang et 
al., 2007). Additionally, COX-1 protein has a very long half-life (Bunimov et al., 2007; Kang et al., 
2007). According with these observations, the expression of COX-1 protein was measured up to 72 
hours after fibroblast stimulation with a pro-inflammatory cytokine. The results show increased levels 
of COX-1 in control-NM tissue, but not in NM-AIA or NPs with or without aspirin intolerance. Altered 
expression of COX-1 in patients who suffer from NP combined with AIA might contribute to the low 
levels of PGE2 detected in patients with NP-AIA. In fibroblasts from BM tissues, the stimulation with 
the pro-inflammatory cytokine appears to increase the expression of COX-1 in both control subjects 
and AIA patients, without differences, as previously reported at baseline. Since previous studies 
observed alterations in the regulation of COX-1 in fibroblasts from patients with AIA, similar results 
were expected in BM-AIA. However this was not verified. Despite, the number of samples to evaluate 
the expression of COX-1 in fibroblasts from BM was limited, there was a clearly increase in its 
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expression after stimulation with the pro-inflammatory cytokine. To confirm the results it would be 
necessary to increase the number of samples, and probably performed different techniques.  
There has been accumulating evidence demonstrating the regulatory role of PGs in inflammation. In 
particular, a number of studies focused on the feedback control of COX-2 (Vichai et al., 2005). 
However, the results presented in these investigations have been varied and largely dependent of the 
cell type. Studies using human synovial fibroblasts, monocytes and the prostatic carcinoma cell line 
(PC-3) showed positive effects of PGE2 on COX-2 (Faour et al., 2001; Hinz et al., 2000; Tjandrawinata 
and Hughes-Fulford, 1997), whereas a study using the human umbilical vein endothelial cell line 
showed that PG downregulated COX-2 protein synthesis (Akarasereenont et al., 1999). A previous 
study performed in mouse lung fibroblasts reported a positive feedback on the regulation of COX-2 
expression by PG metabolites, as PGE2, in the presence of an inflammatory stimulus, but not on the 
regulation of COX-1 expression (Vichai et al., 2005). The same authors hypothesized that the 
induction of COX-2 protein expression by both PGE2 and IL-1β might result in the activation of 
different pathways and that a product of IL-1β-responsive gene might enhance COX-2 inducing PGE2 
activity. On the basis of these observations and in order to analyze if PGE2 alone, i.e., in the absence 
of a pro-inflammatory stimulus, induce the expression of COX-1 and COX-2 enzymes, fibroblasts were 
incubated with PGE2, for 24 hours, and the expression of both enzymes was measured. The results 
showed that PGE2 is able to increase alone the expression of COX-1 enzyme, without differences 
between the tissues under analysis, i.e., there are no differences between control subjects, AT and 
AIA patients. These findings suggest the presence of a mechanism by which PGE2 regulates the 
expression of COX-1, without the presence of an inflammatory stimulus. On the other hand, when 
COX-2 was analyzed, it was not detected any expression of the enzyme. Considering these results, it 
is possible that COX-2 protein is only expressed under inflammatory conditions, and the PGE2 alone is 
not able to induce the expression of this enzyme. Moreover, it is possible that the concentrations of 
PGE2 used in this study regulate negatively the expression of COX-2. However, the multiplicity of 
components involved in this signalling pathway probably complicates the process of regulation, and 
more studies are necessary to confirm these findings.   
 
 
4.3. EP Receptors Expression 
PGE2 is normally considered a potent pro-inflammatory mediator, actively involved in the pathogenesis 
of several diseases. However, in the lungs, PGE2 has functions that reduce airway hyper-
responsiveness and inflammation, as well as that control tissue repair (Vancheri et al., 2004). The 
ability of PGE2 to induce or suppress several mechanisms involved in inflammation indicates the 
complex activities of its receptors (Kang et al., 2007). The EP receptors (EP1-EP4) signal through 
distinct pathways and the expression of their genes is regulated by various physiological and 
pathophysiological stimuli (Sugimoto and Narumiya, 2007). Considering these data, it was 
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investigated the levels of each EP receptor in fibroblasts, at baseline and after cell stimulation by the 
action of a pro-inflammatory stimulus, since some receptors required cell activation.  
At baseline and after cell stimulation with a pro-inflammatory cytokine, the expression of EP1 receptor 
was not detected. The lack of detection can be due to the low expression of this receptor in the cells 
used to perform the experiment or to the methodology used, which might present some technical 
limitations. Burgess and collaborators, in a previous study to assess the presence of EP receptors on 
airway smooth muscle cells isolated from asthmatic patients and non asthmatic individuals, also failed 
to detect the presence of EP1 receptor by means of ELISA (Burgess et al., 2004). However, there are 
several studies that reported the presence of this receptor in different cell types, and different 
methodologies are used to perform the analysis (Ying et al., 2006; Pérez-Novo et al. 2006; Roca-
Ferrer et al., 2011).  
In basal conditions, a previous study (Roca-Ferrer et al., 2011) did not found any differences in the 
expression of EP1 through EP4 receptors among fibroblasts from control-NM, NP-AT, or NP-AIA 
tissues. However, Ying and collaborators in a study performed to compare EP receptor expression in 
aspirin intolerant and tolerant patients showed a reduced number of eosinophils, neutrophils, mast 
cells and T cells that express EP2 in NP-AIA samples (Ying et al., 2006). The results presented in this 
study are in agreement with these last findings, since it was reported low basal expression of EP2 in 
fibroblasts from NP-AIA tissue. Additionally, it was also reported an increase in the expression of EP2 
receptor in fibroblasts from NP-AT tissues. Effectively, in a previous study it was demonstrated that 
EP2 receptor is up-regulated in patients who suffer from CRS with NP compared with control subjects 
(Pérez-Novo et al., 2006). According with these findings, when fibroblasts are stimulated with a pro-
inflammatory cytokine, the expression of EP2 is increased in fibroblasts from control-NM and NP-AT, 
but not in fibroblasts from NP-AIA. Roca-Ferrer et al, in a previous study, reported an increase in EP2 
expression in cells from control-NM after stimulation with IL-1β, but not in NP-AT tissues. However, it 
appears to be increased, although without statistical differences (Roca-Ferrer et al., 2011). Most of the 
anti-inflammatory effects of PGE2 are mediated through the EP2 receptor. Considering that, the 
expression of EP2 in NP-AT samples could be increased as a compensatory mechanism. Additionally, 
this compensatory mechanism could be not present in NP-AIA samples, since the expression of EP2 
receptor in these samples is lower when comparing with control-NM and NP-AT samples.  
Signalling through EP3 is known to be both pro-inflammatory and anti-inflammatory. Coupling of PGE2 
to EP3 potentiates mast cell degranulation, which enhances inflammatory processes. Contrary, it has 
been reported recently that EP3 is involved in the suppression of allergic inflammation in an animal 
model of asthma (Kim et al., 2007). A previous study showed that EP3 transcripts were significantly 
decreased in patients with CRS and NP (Pérez-Novo et al., 2006). These findings are in agreement 
with the results obtained in this study, since at baseline low expression of EP3 was observed. In 
fibroblasts from NP samples the expression of EP3 receptor was increased after stimulation with the 
pro-inflammatory stimulus. However, this increase was only significant in fibroblasts from NP-AIA 
tissues. EP3 receptor is known to have multiple splice variants, which complicate the interpretation of 
Discussion 
58 
 
the different results obtained. However, and considering the high expression of EP3 under 
inflammatory conditions, this receptor could play a role in upper airway inflammation. 
The EP4 receptor appears, in some studies, to play a pro-inflammatory role in the pathogenesis of 
some diseases, as rheumatoid arthritis. Additionally, mice deficient in the EP4 receptor exhibits an 
attenuated inflammatory response, since the levels of pro-inflammatory cytokines are significantly 
reduced, as well as the clinical signs of the disease (Hata and Breyer, 2004). In contrast, a recent 
study demonstrated that the EP4 receptor is responsible for PGE2-induced relaxation of human airway 
smooth muscle (Buckley et al., 2011), which indicates that this receptor also possesses anti-
inflammatory proprieties. Pérez-Novo and collaborators reported that EP4 receptor is up-regulated in 
subjects who suffer from CRS with NPs compared to control individuals (Pérez-Novo et al., 2006). In 
this study, it is reported an increased expression of EP4 receptor in fibroblasts from NP-AIA tissues. 
On the basis of the observations previously presented, the high expression of EP4 in fibroblasts from 
NP-AIA could represent a compensatory mechanism.  
 
 
4.4. Limitations of the Study 
This study presents some limitations. Since our experimental model is based on primary cell cultures 
i.e., explants taken directly from the living organism in order to preserve, as well as possible, the 
characteristics of each patient, and considering that each cell line is respective to a unique individual, 
the current investigation was limited, mostly, by the lower number of BM samples available to perform 
the study, as well as by the high inter-sample variability verified in some results. For these reasons the 
comparison between upper and lower airways was not always clear. Considering that it would be 
important to increase the number of samples of both BM tissues (control and AIA), and to perform 
different techniques in order to minimize the variability and to obtain results more robust about the 
regulation of the different component of the COX pathway.  
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5. Conclusions and Future Perspectives 
New insights concerning inflammatory airway diseases, as asthma, nasal polyposis, CRS, and aspirin 
intolerance, and their respective mechanisms are important, since these syndromes have a high 
prevalence, and affect the quality of life of several individuals. This investigation was important since it 
allowed draw some conclusions about the metabolism of the AA pathway, more specifically, about the 
components of the COX pathway, i.e. COX enzymes, PGE2 and its respective receptors. Moreover, for 
the first time, it was established a comparison between the AA metabolism regulation in the upper and 
lower respiratory tracts of patients without asthma who are tolerant to aspirin, patients with asthma 
who are intolerant to aspirin, and control subjects. Some studies reported alterations in COX pathway 
in upper and lower airways, but others not found any differences. Different methodologies and 
samples used in each investigation are the most probable cause for these contradictory results. For 
these reasons, and due to these limitations, the role of COX pathway in the pathogenesis of aspirin 
intolerance was not completely elucidated, and additional studies are necessary to clarify the 
mechanisms responsible for the syndrome. It is clear that there are differences between upper and 
lower airways, and, it is interesting that in lower airway the presence of aspirin intolerance does not 
seems to alter the regulation of the expression of COX enzymes or the secretion of PGE2, as previous 
studies have shown. Effectively, patients with AIA often suffer from nasal polyposis. However, polyps 
are never seen in the lower airways of patients with bronchial asthma. In this case, the differential 
regulation of COX enzymes and PGE2 may play a role at this level. Additionally, it has been 
demonstrated that PGE2 is able to induce the expression of COX-1. So, future studies would be 
necessary to investigate the signaling pathway by which PGE2 regulates COX-1. Moreover, and 
considering that PGE2 is able to induce COX-1, which EP receptor is involved in this stimulation? 
Further studies using selective agonists and antagonists of EP receptors would be useful to 
investigate the EP receptor subtype mediating the PGE2-stimulated COX-1.  
The effect of eicosanoids in the tissue is greatly dependent of the differential expression of the distinct 
subtypes of their receptors (Pérez-Novo et al., 2006). Considering this observation it is important to 
understand the pattern of expression of the EP receptors (EP1 through EP4) in the inflammatory 
airway diseases, to increase the knowledge about the different actions of PGE2. Unfortunately, in this 
investigation the comparison upper versus lower airways was less clear with respect to EP receptors 
expression, since it was found a great variability in the expression of the EP receptors through the 
lower airways of patients with the same characteristics (control or AIA). However, in this investigation 
differences were found in nasal tissues of patients who suffer from aspirin intolerance, compared with 
AT patients and control subjects. Since the methodology used for the analysis of protein expression 
failed to establish the comparison between upper and lower respiratory tract it would be interesting to 
use other techniques to evaluate the pattern of expression of these receptors. The real time PCR 
technique, for instance, can be used to evaluate and measure the mean levels of EP mRNA 
expression in the same samples analyzed in this study.  
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These findings together with further studies on COX enzymes, PGE2 and EP receptors regulation in 
control subjects and patients with inflammatory airway diseases may help to establish new 
diagnostics, and to improve current and explore further therapies for the attenuation of the symptoms 
or for the treatment of the inflammatory diseases discussed in this investigation. 
In summary, this study describes the regulation of the different components of the COX pathway in 
upper and lower airways of patients without asthma who are tolerant to aspirin, patients with asthma 
who are intolerant to aspirin, and control subjects. Significant differences in the expression of COX-1 
and COX-2 enzymes, as well as in the secretion of PGE2 were reported when upper and lower 
airways were compared. The data presented in this investigation suggest that in lower airways, the 
presence of aspirin intolerance does not seems to alter the expression of COX-1 and COX-2 enzymes 
or the production of PGE2, as verified in upper airways of patients with AIA. These results suggest a 
differential regulation between upper and lower airways, which can be involved in the pathogenesis of 
nasal polyposis. Considering the expression of the EP receptors, the data suggest differences through 
fibroblasts from upper airways tissues. However the significance of the differences in EP expression 
reported in this study must be confirmed by functional studies using selective agonists or antagonist of 
these receptors. The differences between upper and lower airways described, combined with others 
observed in previous studies might contribute to the pathogenesis of nasal polyposis. 
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